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Post-transcriptional RNA modifications provide new structural and functional features to 
modified RNA molecules. Extensive research in the past has resulted in isolation of over 100 
distinct nucleotide modifications from different organisms and in different RNA species. These 
modified nucleotides are distributed within the entire transcriptome comprising the cellular 
epitranscriptome.  The ultimate goal of the research in the field is to address what the specific 
functions of specific modifications are, and also the impact of each on cellular physiology. 
However, the first question to be addressed is how these > 100 modified nucleotides are 
distributed within the transcriptome.    
RNA modification profiling using conventional techniques has provided a great body of 
knowledge about the distribution of many modifications in RNAs. However, these findings 
remained limited mostly to tRNAs and rRNAs, the two most abundant and also highly modified 
RNA species in different organisms. This is partly because of the lower sensitivity of applied 
classical technologies.  
Here in this dissertation, in Chapter 2, we are reporting an optimized new RNA bisulfite 
protocol suitable for high-throughput RNA cytosine methylation profiling. We present the 
results of application of this technique for 5-methyl-cytosine (m5C) profiling in mouse embryonic 
fibroblasts (MEFs) RNAs, isolated from wt and dnmt2-/- mice to explore the target specificity of 
DNA methyltransferase 2 (DNMT2) enzyme.  
In Chapter 3, we present a substantially novel technique: Aza-IP, for enrichment and 
identification of the direct targets of RNA cytosine methyltransferases (m5C-RMTs) as well as 
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determination of the exact modified bases in the same experiment.  We provide the results of 
the Aza-IP technique for two human m5C-RMTs; DNMT2 and NSUN2, representing their known 
and novel RNA targets/modified bases.  
In Chapter 4 we discuss how similar technologies to both of the RNA bisulfite 
sequencing and Aza-IP techniques as well as other methodologies can be applied and extended 
for transcriptome-wide profiling of RNA modifications other than m5C.    
In Chapter 5 we present the future directions of the work focused on cataloguing the 
direct targets of all human m5C-RMTs in human cultured cells in mouse and fish model systems, 
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Modifications and flow of genetic information 
The three fundamental informative polymers of life - DNA, RNA and proteins - are 
polymerized from nucleotides, ribonucleotides and amino acid building blocks, respectively. 
DNA, in most organisms, exists in double-stranded form and serves as the information storage 
polymer consisting of only four standard nucleotides: A, C, G and T. To decode and utilize the 
stored information in DNA, different types of RNA polymerases transcribe the DNA at specific 
defined locations to produce variety of single-stranded RNA molecules by accurately copying the 
sequences from DNA to RNA transcripts. The RNA molecules, again, are composed of only four 
standard ribonucleotides: A, C, G and U. A portion of RNA transcripts – mRNAs - code for protein 
synthesis in ribosomes to translate every triplet codons within mRNAs, into one amino acid in 
the polypeptide chains. The protein molecules are composed of 21 standard amino acids.  
Although the limited number of aforementioned building blocks in each polymer type 
seems to be necessary for the natural flow of genetic information from DNA to RNA to protein, 
they are not sufficient to fulfill all expected functions of such polymers in living organisms. Thus, 
although DNA, RNA and proteins are built from only few standard building blocks, some of the 
monomers at specific defined locations may undergo some targeted enzymatic changes to 
produce new modified entities. These postreplicational, -transcriptional or – translational 
modifications provide new structural and/or functional features for these polymers making 
them suitable to fulfill more elaborated functions and through more controlled/regulatable 
ways. Thus, understanding the full spectrum of modified building blocks, their exact positions 
within the polymers, their actual functions - as well as studying the effector proteins/enzymes 
producing (writing), interpreting (reading) or removing (erasing) those modified entities - is 




Diversity of RNA modifications 
Naturally modified nucleotides in DNA molecules are limited (6-methyladenosine (m6A), 
5-methylcytosine (m5C), 5-hydroxymethylcytosine (hm5C), and the Base J1), whereas more than 
100 distinct modified structures have been identified so far in RNA, and the list is still growing2 
(Figure 1.1). From a chemical standpoint, the DNA and RNA polymers are substantially similar in 
structure with two exceptions: presence of hydroxyl group at 2’ position of the ribose in RNA 
and replacement of T in DNA with U in RNA which differs only in one methyl group. Also, DNA is 
mostly double-stranded while RNA is largely single-stranded (although it can make local double-
stranded structures as well). The majority of modifications taking place in RNA are chemically 
possible to take place in DNA as well, but the observed number of modifications in DNA is much 
below the expected numbers.  This significant difference in the numbers may reflect the 
resistance of DNA during evolution, as an information storage entity, to accommodate more 
modifications in order to maintain the fidelity and integrity of information during DNA 
replication. This will become more clear when considering that some modified nucleotides can 
change the A:T or G:C base pairing rules, and therefore can cause mutations, and some others 
may stop the polymerases during replication, and therefore can cause interruption in DNA 
synthesis and duplication, impairing the normal cell cycle and division.  
RNA in contrast is not the information storage polymer, except in some RNA viruses, and 
once it is transcribed it no longer serves as the polymerization template, except in the case of 
telomere maintenance and in retroviruses and retrotransposons. This has probably allowed the 
RNA molecules to accommodate such a diverse pool of modified entities. In addition, RNA has 
diverse responsibilities in living organisms including coding, transfer, catalytic, structural, 
regulatory or guide functions which all can become enhanced or regulated by post-





Figure 1.1 | Diversity of nucleotide modifications in RNA2.  This schematic, from reference,2 




The emerging concept of “epitranscriptome”  
Although modified nucleotides have been observed in almost all RNA species, tRNAs and 
rRNAs harbor majority of known RNA modifications regarding both of the number and diversity. 
Results obtained over the past five decades, from classical RNA profiling approaches, suggest 
that most known RNA modifications reside in tRNAs and rRNAs but not other RNA species. 
mRNAs, snRNAs, snoRNAs etc., are believed to show less diverse and lower numbers of 
modifications, in comparison to tRNAs and rRNAs. Since tRNAs and rRNAs are both highly 
abundant and highly modified in cells, it has been easier to isolate the RNAs and characterize 
these modifications. However, these advantages for studying modification in these two RNA 
species may be considered disadvantages for studying modifications in other RNA species using 
classical methodologies. This is because preparing pure RNA samples of low-copy RNA species 
from cell extracts without contamination by highly abundant tRNAs and rRNAs  (which are also 
highly modified), is almost impossible. This will result in higher background, lower resolution 
and difficulties in interpretation of RNA modification profiling, which limits the detection of less 
abundant and slightly-modified RNA species. On the other hand, in recent years, several new 
noncoding RNA (ncRNA) species have been characterized in different organisms, which are 
considered new targets of RNA modification profiling as modified nucleotides have already been 
isolated in some of them. These challenges prompt the need for development of sensitive 
discovery tools to unravel the real scope of RNA modifications in all RNA species to define the 
“epitranscriptome” of living organisms. This may be possible by recruiting and/or modifying the 
recently developed and still evolving high-throughput modification profiling techniques.  
Here in this dissertation we explain and exemplify the cytosine 
methylation/methyltransferases and cytosine methylation profiling methodologies extendable 
for studying other types of RNA modifications / modifiers.  
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5-methylcytosine in DNA 
5-methylcytosine (m5C) is the first modified nucleotide described in 1948 in DNA.3 Since 
then the functions and enzymology of m5C-methylation have been the focus of extensive 
research in many laboratories worldwide. This endeavor has resulted in generation of a massive 
body of knowledge about m5C in DNA, the DNA methyltransferase enzymes (DNMTs), the m5C 
binders (MBD proteins), the de-methylase complexes as well as physiological attributes and 
pathological implications of disruptions or misregulation of DNA methylation machinery.4  
 
5-methylcytosine in RNA 
m5C has been found in many RNA species.5, 6 Majority of m5C bases in total cellular RNAs 
are present in tRNAs as they are both abundant molecules and bear more m5C sites considering 
their short length of approximately 75 bp on average.  tRNAs of archaeal and eukaryotic origin, 
not eubacterial organisms, contain m5C at specific conserved locations.5 In humans over 200 
m5C distinct sites have been identified in different tRNAs and their isoacceptors (tRNAs with 
different anticodons that accept the same amino acid) or isodecoders (tRNAs with the same 
anticodons that accept the same amino acid but have different body sequences).6 However, the 
most conserved and frequently modified sites within various tRNAs of different species are C48 
and C49 positions at the junction of variable region with TΨC-stem of tRNAs.5, 6  
Prokaryotic and eukaryotic rRNAs also show conserved m5C sites indicating functional 
importance. However, compared to tRNAs, rRNAs, with much longer length, show much lower 
number of m5Cs. For example there are only three m5Cs reported in Escherichia coli rRNAs, two 
in human 28S and none in the many eukaryotic 18S rRNAs that have been identified so far.5 The 
scope of ribosomal m5C methylation in different species, however, remained to become fully 
7 
 
explored as it is possible that only a subset of rRNAs receive this modification, which may be 
missed using available analysis tools.  
m5C has also been reported previously in mRNAs and also some viral RNAs such as 
sindbis virus, adenovirus and Turnip Yellow Mosaic Virus (TYMV) RNAs.7-11 Finally, a recent high-
throughput RNA methylation profiling by bisulfite sequencing in HeLa cells verified and 
extended m5C presence in tRNAs and rRNAs, and also showed m5C in other noncoding RNAs as 
well as a limited number of mRNAs.6 These recent results in HeLa cells motivate a more 
thorough examination of the scope (cell types and developmental contexts) and functions of 
this modification. 
 
RNA cytosine methyltransferases (m5C-RMTs) 
All m5C sites in all bacterial, archeal and eukaryotic organisms are laid down 
enzymatically by the action of RNA cytosine methyltransferases (m5C-RMTs).5 Different types of 
m5C-RMTs have been characterized so far that all catalyze the methyl transfer from the methyl 
donor S-Adenosyl Methionine (SAM) cofactor to the fifth position (C5) of the target base 
cytosine producing methylated RNA and S-Adenosyl-L-Homocysteine (SAH) as the product and 
byproduct of this reaction, respectively.5 All m5C-RMTs tested so far, similar to DNMTs, form a 
covalent enzyme-substrate intermediate with their target cytosine through the sulfur atom of 
the cysteine residue in their catalytic domain to the C6 position of the base in the target RNA. 
Next enamine methylation of the C5 position of the target cytosine is catalyzed by the enzyme 
using SAM as the methyl donor, followed by beta-elimination to complete the methylation cycle 
and releasing the enzyme5 (Figure 1.2). This catalytic mechanism is the basis for design and 
construction of DNMT and m5C-RMT suicide inhibitors such as 5-azacytidine (5-aza-C).12 RNA 








Figure 1.2 | Mechanism of RNA cytosine methylation by m5C-RMTs.5  This schematic, from 
reference,5 represents the detailed mechanism of RNA cytosine methylation by m5C-RMTs. 
Upon recognition of the exact target cytosine within an RNA molecule a conserved cysteine 
residue from the catalytic site of the m5C-RMT makes a covalent connection to the 6th position 
of the target cytosine through Michael addition. Next a methyl group is transferred from the 
methyl-donor; SAM, to the 5th position of the target base through enamine methylation. Finally 
the cysteine residue is released from the base through beta elimination resulting in methyl-
cytosine and SAH as product and byproduct of the methylation reaction, respectively.  
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cytosines. 5-aza-C, once incorporated at the target site, can block the m5C-RMTs.  Due to 
substitution of carbon atom at position 5 of the base with nitrogen in 5-aza-C, the methylation 
cycle cannot be completed and the enzyme remains covalently attached to the base. This RMT-
RNA adduct formation depletes the cells from m5C-RMTs resulting in RNA hypomethylation.12-15  
Based on the exact catalytic mechanism there are two types of m5C-RMTs.5 Members of 
the first enzyme type, exemplified by DNMT2 enzyme, for methylation use a single cysteine in 
their catalytic site similar to the action of DNMTs.16 In contrast members of the second type, 
exemplified by the members of NSUN family of RNA methyltransferases, utilize two different 
cysteine residues from separate domains in their catalytic site for the catalysis. In this second 
enzyme type, one cysteine form the covalent connection with the cytosine base and after the 
completion of methyl transfer from SAM to the C5 of the base the second cysteine residue 
triggers the release of the base from the enzyme17 (Figure 1.3). For the two cysteine enzyme 
type, substitution of the second cysteine residue with another amino acid impairs the 
completion of methylation cycle and results in formation of stable m5C-RMT-RNA adduct 
through the covalent connection between the sulfur atom of the first cysteine residue from the 
enzyme to the C6 position of the target cytosine base within the target RNA molecule.18, 19  
Based on structural and functional properties, m5C-RMTs have been subdivided into six 
families: RsmB/Nol1/NSUN1, RsmF/YebU/NSUN2, RlmI, Ynl022, NSUN6 and DNMT25 (Table 1.1). 
RsmB/Nol1/ NSUN1-family members are conserved, with known substrates (16S rRNA) in E. coli 
but not in eukaryotes.5 RsmF/YebU/NSUN2-family enzymes are also conserved, and methylate 
16S rRNA in bacteria or tRNA in eukaryotes, though orphan enzymes exist, with unknown 
substrates.5 Most tRNAs and several noncoding RNAs have been shown to be the substrates of 








Figure 1.3 | Differences in the mechanism of cytosine methylation by RNA and DNA cytosine 
methyltransferases.5  This schematic, from reference,5 represents the differences between the 
catalytic mechanism of RNA cytosine methyltransferases (m5C-RMTs) (left) and DNA cytosine 
methyltransferases (DNMTs) (right). Most m5C-RMTs including members of the NSUN family of 
methyltransferase utilize two cysteines in their catalytic domain. The cysteine residue from 
motif VI makes the covalent connection and enhances the methylation reaction. The cysteine 
residue from motif IV then drives the reversal of the covalent connection and release of the 
enzyme from the base.  In contrast, all DNMTs, and also the RNA methyltransferase DNMT2, 






Table 1.1 | Some known and putative m5C-RMTs.5  This table, from reference,5 represents 
some classified information about different RNA cytosine methyltransferases (m5C-RMTs), 







rRNA5. Ynl022 family members are solely eukaryotic, and lack defined substrates.5 NSUN6 is 
found in vertebrates, and lacks a defined substrate.5 DNMT2 is now known to function primarily, 
if not exclusively, as an m5C-RMT, with three verified tRNA targets: tRNAAsp, tRNAGly and 
tRNAVal.20, 21  
 
Functions of m5C in RNA 
The precise locations of many m5C sites within noncoding RNAs from divergent species 
are very well conserved during evolution.5 This is more pronounced in tRNAs partly because 
they have been studied more. m5C at C40 of the S. cerevisiae tRNAPhe has been shown to be 
required for proper Mg2+ binding triggering the conformational transition of the anticodon 
loop.22 m5C at C34, the anticodon wobble base of leucine tRNAs in S. cerevisiae, has been shown 
to be important for efficient suppressor activity of the leucine-inserting amber suppressor 
tRNA3Leu.23  
The m5C sites in ribosomal RNA tend to cluster in close proximity within the ribosomal 
3D structure and this is despite the distant locations of m5C sites within the linear rRNA 
sequences, indicating the functional importance of m5Cs.22 Notably, the antibiotic paromomycin 
binding site has been mapped to the exact same region in the ribosomes. Paromomycin inhibits 
the protein synthesis through binding to the ribosomal RNA. Interestingly the yeast strains 
lacking the corresponding m5C-RMT enzyme show greater sensitivity to this antibiotic.24  
Beside these few examples and despite several decades of efforts the exact biological 
functions of m5C in RNA remain elusive. However, the importance of m5C methylation in RNA 
can become conferred from some severe phenotypic manifestations of the depletion, or 
misregulation of corresponding m5C-RMTs in different organisms. For example upregulation of 
NSUN1 and NSUN2 has been documented in many cancer cell lines or tumor types.25-27 NSUN2 
13 
 
functions are linked to Myc-induced proliferation of cancer cells,28 mitotic spindle stability,29 
infertility in male mice, and balancing self-renewal/differentiation of stem cells in the skin.30 
Most importantly, NSUN2 mutations cause an autosomal recessive syndrome in humans 
conferring intellectual disability and mental retardation.31-33 Other members of the NSUN family 
of RNA methyltransferases are also linked to abnormalities such as genetic disorders (NSUN5 
variants) and fertility (NSUN7).5, 34, 35  
Most organisms lacking DNMT2 lack obvious phenotypes,36 though zebrafish display 
developmental perturbations.37 Notably, DNMT2 activities attenuate tRNA cleavage during 
stress conditions,21 contribute in RNA processing in stress granules38 and promote the virus 
response to positive strand RNA viruses in Drosophila Melanogaster.39 Moreover, tRNA cytosine 
methylation by both DNMT2 and NSUN2 homologues promotes tRNA stability and steady-state 
protein synthesis.40 
Overall, although efforts in the past and recent discoveries have increased the scope of 
RNA cytosine methylation, and also revealed a large number of candidate m5C-RMTs, the exact 
functions of m5C sites in RNAs along with the functions and targets of many known and 
candidate m5C-RMTs remain elusive. 
 
m5C RNA methylation dynamics 
Studying the dynamic changes of m5C levels in DNA is indispensable from epigenome 
research. Similarly, one interesting question in the epitranscriptome field is whether there is 
such an analogy for RNA modifications like m5C methyl marks in RNA molecules. Analogous to 
regulated methylation as well as passive and active DNA demethylation concepts, RNA 
methylation dynamics could be achieved by any of: RNA turn-over, regulated and targeted 
methylation, or demethylation. The balance between transcription and RNA decay rates with 
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methylation rates is a key determinant of RNA methylation dynamics. On the other hand the 
RNA methylation level at a particular target site and/or differential methylation of target sites in 
different conditions can become potentially regulated by external factors during stress 
conditions or immune response, or upon induction by a chemical or biochemical stimulus.  
Finally, erasing the methyl marks through active enzymatic demethylation is another possibility 
to achieve the dynamic methylation changes in RNA.  
Quantification of tRNA modifications in Saccharomyces cerevisiae using a precise mass 
spectrometric method in a recent work, demonstrated that some modifications, including m5C, 
show dynamic changes upon exposure of cells to different toxicants.41 Specifically m5C, in 
parallel with some other modifications such as Cm and m22G, shows significant increase 
following hydrogen peroxide exposure, suggesting a possible contribution of dynamic RNA 
modifications in stress response.41 Subsequent analysis of substrates of an RNA cytosine 
methyltransferase; Trm4, provided a model for involvement of dynamic m5C methylation in 
stress response.42 Trm4, the human NSUN2 homologue in yeast, is responsible for methylation 
of C34, the wobble position, in tRNALeuCAA anticodon. Oxidative stress induces significant 
increase in the methylation level at C34 in this tRNA resulting in increased translation of genes 
with enriched TTG codon notably RPL22A; a ribosomal protein. Hypersensitivity to oxidative 
stress upon loss of either of Trm4 or RPL22A proteins has been observed indicating the 
important role of RNA modification-mediated selective protein translation during stress 
response.42 
Another example of regulated m5C RNA methylation is the recent work showing the 
significant nutritional status-dependent increase in the methylation level of C38 in tRNAAsp in 
fission yeast. Interestingly, this regulation requires a specific serine/threonine kinase; Sck2, 
clearly linking the nutrient signaling and RNA modifications pathways. Pmt1, the human DNMT2 
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homologue in Schizosaccharomyces pombe, is responsible for C38 methylation in tRNAs.43 It is, 
however, not clear whether the Pmt1 enzyme or its protein partners are the targets of Sck2 or 
which residue(s) is (are) the targets of phosphorylation, and most importantly what the 
consequence of C38 methylation during nutrient deficiency is.  
Beside regulating the levels and target sites of RNA modifications, erasing the 
preexisting marks can potentially affect the modification status of RNA molecules. This has been 
recently very well documented for the case of RNA adenosine methylation (m6A) by isolating 
and characterizing the demthylase complexes.44 Similarly, in explaining the m5C dynamic 
changes, although there is no direct evidence for the demethylation scenario, it is a possibility 
that some m5C marks on RNA become erased enzymatically. Interestingly hyroxymethyl-cytosine 
(hm5C) has been reported in some eukaryotic ribosomal RNAs.45 Here, m5C hydroxylation may 
be considered as an intermediate step in erasing the methyl marks, analogues to Tet protein 
mediated hydroxylation of m5Cs in DNA as a prerequisite for the demethylation procedures. 
Thus, it would be interesting to know whether there is an overlap between the sites of m5C and 
hm5C marks within the RNA molecules and also probe for identification of possible m5C 
demethylase complexes by sequence homology surveys.  
 
m5C profiling methodologies 
The first step in RNA modification studies of any kind is to find out what RNA molecules, 
at which specific location(s), and to what extent are modified. The “RNA modification profiling” 
term refers to this effort. Different strategies have been used in the past to isolate the modified 
RNA molecules and define their sites and levels of modifications. Almost all these strategies rely 
on the differential behavior of unmodified and modified nucleotides during the modification 
profiling procedures. Most modified nucleotides including m5C can become determined by 
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techniques which differentiate the molecules based on their physicochemical properties such as 
electrophoresis, chromatography and mass spectrometry methods.46 The exact location of most 
of the tRNA and rRNA m5C sites have been determined long ago using these technologies.5, 45  
The locations of some of these sites as well as their responsible methyltransferases have 
become confirmed by reconstitution of methyltransferase reactions (MTase assays) in-vitro 
using purified m5C-RMTs and RNA substrates followed by chromatography or mass 
spectrometry analysis.5   
Finally, a few years ago, based on the differential chemical reactivity of Cs vs m5Cs with 
sodium bisulfite mixture, a version of bisulfite sequencing technique suitable for RNA molecules 
adapted (with some modifications) from DNA bisulfite sequencing methods, proved to be able 
to precisely report the m5C sites in RNA molecules.47 Recently, a similar approach was used to 
identify the first transcriptome-wide RNA m5C methylome by performing a high-throughput 
sequencing of the bisulfite treated RNAs isolated from HeLa cells.6 This work verified and 
extended the repertoire of m5C presence in RNA motivating a more thorough examination of 
the scope (cell types and developmental contexts) and functions of this modification. 
 
Preview 
Here in this dissertation we will discuss the recent improvement of epitranscriptome 
profiling technologies, made by us and others.  
In Chapter 2, we present a modified RNA bisulfite sequencing approach which reports 
the m5C sites with high-fidelity and minimum false positive rates. We have applied this 
technique for exploring the RNA methylome of mouse embryonic fibroblasts (MEFs) and 
compared the RNA methylome of wt vs. Dnmt2-/- MEFs to find the Dnmt2 RNA targets.  
17 
 
In Chapter 3, we introduce a novel mechanism-based enrichment technique; Aza-IP, for 
enrichment of the RNA target molecules of all m5C-RMTs and isolation of the exact target sites 
within the same experiment. We present the results obtained with Aza-IP for both of human 
DNMT2 and NSUN2 in HeLa cells.  
In Chapter 4, we discuss how similar concepts can be used to study the other RNA 
modifications and modifiers to provide a high-resolution picture of combinatorial RNA 
epitranscriptome. We also review all available tools and technologies for epitranscriptome 
profiling in general.  
In Chapter 5, we discuss the on-going projects and future directions of the work with the 
aim of providing a comprehensive catalogue of the direct targets of all human m5C-RMTs in 
tissue culture and selected mouse or zebrafish m5C-RMTs in-vivo. Our eventual goal for all these 
experiments is to elucidate the rules and roles of RNA cytosine methylation in living organisms.  
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HIGH RESOLUTION TRANSCRIPTOME-WIDE RNA CYTOSINE  





Differential behavior of cytosine and 5-methyl-cytosine (m5C) nucleotides in exposure to 
sodium bisulfite mixture at acidic pH, has provided a valuable tool for sequencing-based 
methylation profiling of the genomic DNA.1 In principle upon bisulfite treatment, all of the 
unmethylated Cs are deaminated and get converted to U, appearing as T after sequencing, while 
m5Cs are refractory to this deamination and remain as Cs after sequencing, an indication of the 
sites of cytosine methylation. The so called bisulfite sequencing method can define the 
methylation pattern of individual DNA strands, in single base resolution, and has been 
successfully scaled up to define the entire eukaryotic genomic DNA methylomes in coupling with 
high-throughput sequencing.2-4  
Bisulfite treatment, however, for the second important nucleic acid polymers of the 
living organisms, the RNA, has been used for more divergent applications in the past. More than 
four decades ago Shapiro et al. published the first report on specific deamination of cytosine 
bases in RNA molecules by sodium bisulfite treatment at acidic pH and also demonstrated that 
bisulfite mediated deamination requires the exposure of cytosines in the single stranded nucleic 
acid forms.5 Taking the advantages of these two features, bisulfite treatment was used for 
defining the secondary structures of bacterial ribosomal RNA, with the fact that bisulfite ions 
cause C to U conversion of only the exposed cytosines but not the Cs in the C-G hydrogen 
bounds within the double stranded regions.6 High-throughput sequencing of the bisulfite 
treated RNA, has also been used for distinguishing the sense from antisense transcripts, prior to 
the availability of the directional cDNA sequencing, with the fact that bisulfite conversion 
changes the sequence context in the way that the sense and antisense strands are no longer 
completely complementary and therefore distinguishable from each other.7  
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m5C nucleotides have been detected in many RNA species in organisms from all three 
kingdoms of life and it is interesting to find their exact positions within the RNA molecules.8 The 
first bisulfite treatment based determination of m5C sites in RNA molecules, backs to the 
mapping of the methylated cytosine in Saccharomyces cerevisiae tRNAHis by primer extension 
over the bisulfite treated RNA.9 Few years later the RNA bisulfite sequencing technique was 
established deliberately for mapping of both known and unknown m5C sites in tRNA and rRNA 
molecules10 and successfully been used later on to find the two new tRNA targets of DNA 
methyltransferase 2 (DNMT2); tRNAGly and tRNAVal beside its known target tRNAAsp.11 This new 
RNA bisulfite sequencing technique, however, showed lower C to U conversion rates (about 95% 
conversion efficiency) when analyzing the larger RNA species, such as 28S rRNA, most likely due 
to the highly structured nature of the molecules bearing a number of partial double stranded 
regions, requiring extended treatment time, which itself, resulted in RNA degradation and lower 
recovery yields.10 Finally in 2012 the first transcriptome-wide high resolution RNA methylome 
was reported for HeLa cells. This work reported over 10,000 m5C sites in tRNAs, mRNAs and 
other non-coding RNAs (ncRNAs) demonstrating that m5C is a widespread modification in 
eukaryotic RNAs. However, since this is the first report and the only existing transcriptome-wide 
RNA methylome analysis and especially because of the short bisulfite exposure time of 4 hours 
at 75oC according to their procedure,12 it is unclear whether all of the reported m5C sites are 
true methylation sites, due to possible incomplete conversion caused by highly structured RNAs 
and also possible mapping errors (see below). Thus validation of the reported m5C sites in this 
work requires reproduction of the results by other groups and /or application of similar 
protocols in HeLa or other cell types. Here, in order to establish a valid and verified bisulfite 
sequencing approach we evaluated the existing recipes and examined multiple parameters, 
testing them at the level of nucleosides, oligonucleotides (methylated and unmethylated, and 
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linear and structured) and total RNA extracted from the cells, to formulize an effective modified 
RNA bisulfite sequencing method. Our new protocol utilizes formamide in the bisulfite mix and 
RNA fragmentation of long RNAs prior to bisulfite treatment to achieve both higher conversion 
rates and higher recovery yields. This new procedure has proven to produce close to 99% 
conversion rate with minimal false positive calls, reliably applicable for high-throughput 
sequencing platforms. Here in this report we present the first high-resolution deep RNA cytosine 
methylomes of mouse embryonic fibroblasts (MEFs) isolated from wild-type (wt) and Dnmt2 null 
mice (dnmt2-/-) demonstrating that at normal conditions tRNAAsp, tRNAGly and tRNAVal are the 
only Dnmt2 targets in MEFs.  
 
Materials and methods 
Bisulfite treatment and HPLC analysis of nucleosides 
In a 1.5ml eppendorf microtube, 480 nmoles of cytosine or 5-methyl-cytosine 
nucleosides were mixed with 120 nano-moles of 2’-deoxy-guanosine (as the internal control) 
and ddH2O was added to the mixture to the final volume of 285μl. In a separate reaction tube, 
312μl of the freshly prepared 5M sodium bisulfite (pH 5) were mixed with 3μl of the freshly 
prepared 100mM hydroquinone and were added to the nucleosides mixture and incubated at 
50°C. After 1.5 hrs 100μl of the reaction mixture were directly injected into the column for the 
HPLC analysis with Polar RP column in 1% TFA buffer. In separate HPLC runs each one of 
Cytosine (C), 5methyl-Cytosine (m5C) and deoxy-Guanosine (dG) nucleosides were injected into 
the same column to draw the reference HPLC peaks. The reference peaks then were overlaid on 




Bisulfite treatment and sequencing of the synthetic RNA oligonucleotides 
Sample preparation: Synthetic linear and structured oligonucleotides (methylated and 
nonmethylated) were used (Table 2.1) to study the efficiency and recovery yield of RNA bisulfite 
sequencing. The structured RNA oligonucleotides were subjected to refolding by mixing each 
one of the oligonucleotides, separately, with hybridization buffer, and heating it up to 75οC and 
letting it to cool down gradually to room temperature. The refolded oligonucleotides were then 
ethanol precipitated and dissolved in RNase free ddH2O. The quality of the hairpin loop 
structure formation was then checked on nondenaturing polyacrylamide gels (PAGE) using 
appropriate size markers. 
Denaturation step: For the bisulfite treatment step, for each of the oligonucleotides, in a 
separate 2ml eppendorf microtube, up to 5μg of the oligonucleotide was mixed with RNase free 
ddH2O (Ambion) to the final volume of 45μl. For the nonformamide containing reactions 240μl 
of ddH2O and for the formamide containing reactions 240μl of deionized 100% formamide was 
added and mixed. The mixtures were then incubated at 95οC for 5min for denaturation. The 
nonformamide containing reactions were directly exposed to the bisulfite reaction mix 
(sulfonation step), while the formamide containing reactions were placed on ice for at least 2 
min (to avoid causing precipitates) prior to exposure to bisulfite reaction mix. 
 
Table 2.1. Oligonucleotide sequences 
Oligo Name Sequence 
60mer linear RNA  5’-GUGUCACAUAGUACCGGAUGUCGACUAAUCGAUAUUGCGCAUCUCGAGUGAAUUCUGAUA-3’ 
Methylated 60mer  
linear RNA  









Bis-R-S 5’- GGTTGGGATGAGTTATTAAAATTTAT-3’ 
* M: methylated cytosine (m5C) 
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Sulfonation step: After denaturation 312μl of the freshly prepared 5M sodium bisulfite 
(PH 5) were mixed with 3μl of the freshly prepared 100mM hydroquinone and were added to 
the nucleosides mixture and incubated at 50°C. For the formamide reaction the tube’s cap was 
tightened by both wrapping parafilm around it and using appropriate plastic clamps. (This was 
important to keep the tube’s cap closed up to the end of the reaction). 
Desulfonation step: illustra NAP-10 Columns (GE Healthcare) were used to get rid of the 
excess amounts of bisulfite ions in the samples. First we equilibrated one column per sample 
with 15ml of RNase free ddH2O. Then we loaded the 600μl of the reaction mix into the column 
and after all of it went through the column 400μl of ddH2O was added and allowed to go 
through the column. Next we added exactly 1ml of ddH20 to the column and collected the 
eluates of each column in a new 1.5ml eppendorf tube (1ml). Then we split each eluate into two 
1.5ml tubes (500μl each) and added 500μl of 2M Tris buffer PH 9.0 (Trizma® Pre-set crystals PH 
9.0 – Sigma-Aldrich), and incubated at 37οC for exactly 2 hrs. 
Recovery: The bisulfite treated RNA molecules were recovered by ethanol precipitation. 
First, 110μl of 3M RNase free Sodium Acetate (Ambion) was added to each of the tubes plus 
10μl of 15mg/ml GlycoBlue (Ambion) and mixed well. The content of each tube was then split 
into 3 new 1.5ml tubes (373μl each) (total of 6 1.5ml tubes per bisulfite treated sample), mixed 
with 933μl absolute ethanol and incubated at -80οC overnight. Next the tubes were spun at 14K 
rpm at 4οC for 20 minutes, the pellets were washed with 1ml of 70% ice cold ethanol one time 
and air dried and dissolved in 10μl of RNase free ddH2O. Next the contents of all 6 tubes of the 
same sample were pooled and stored at -80οC until used. 
RT-PCR, cloning and sequencing: The recovered bisulfite treated RNA oligonucleotides 
were then subjected to reverse transcription reactions (using the forward primer, Bis-F) 
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followed by PCR (using Bis-F as the forward primer for all oligonucleotides, Bis-R-L and Bis-R-S 
for the linear and structured oligonucleotides, respectively, as the reverse primer) (Table 2.1). 
Then the PCR products were cloned individually into TOPO-TA cloning vectors (Invitrogen) and 
used for transformation of Top-10 Ecoli competent cells (Invitrogen) and plated on the ampicillin 
containing plates. The next day several colonies for each experiment were picked and inoculated 
in liquid culture media for plasmid purification. Purified plasmids were then sequenced and 
analyzed to define the conversion rate and the methylation pattern of the bisulfite treated RNA 
molecules. 
 
Bisulfite treatment of the RNA isolated from cultured cells 
To test the efficacy of the formamide-based bisulfite treatment method on biological 
RNA samples, RNA from HeLa cells were isolated using Trizol reagent (Invitrogen) and the quality 
of RNA were tested using Bioanalyzer (Agilent technologies). The isolated RNA was fractionated 
into small and fragmented total RNA fractions containing all large RNAs (fragmented large RNA 
fraction).  The small RNA fraction, isolated by Mirvana kit (Ambion), and the HeLa cells’ total 
RNA was fragmented to about 60-200bp fragments using RNA fragmentation reagent (Ambion) 
at 70οC for 15min according to the manufacturer protocol. Small and fragmented large RNA 
fractions were separately subjected to bisulfite treatment. The recovery yield and RNA integrity 




High-throughput RNA bisulfite sequencing of MEFs samples 
MEF preparation, high-throughput RNA bisulfite sequencing and analysis were done as 
previously described13 and the datasets are publicly available through GEO with the following 
accession number: GSE44359. 
 
Results 
Optimization of the RNA bisulfite sequencing method 
In order to find the best conditions to improve the poor C to U conversion rate of the 
existing methods (especially for the structured large RNAs), and also to increase the recovery 
rate upon extended treatment time, we performed a series of experimental studies over the 
bisulfite conversion kinetics using ribo-nucleosides, synthetic oligo-nucleotides and total RNA 
extracted from cultured cells. We measured the conversion kinetics by bisulfite treatment of the 
cytidine and 5-methyl-cytidine nucleosides. Our analysis showed that the bisulfite mix efficiently 
deaminates cytidine but not 5-methyl-cytidine in a short period of time (< 1.5hrs) (Figure 2.1).  
We then tested the parameters on synthetic methylated and nonmethylated, linear and 
structured short RNA oligo-nucleotides and showed that efficient deamination of all cytosines 
within the RNA polymers in the same bisuflite mix requires longer exposure time of several 
hours. We noticed that majority of Cs were converted in the first hour (data not shown) but full 
conversion of all cytosines was only achieved upon exposure period of 12 hours or more. This is 
likely because of possible base pairing of Cs with neighboring Gs within the same RNA molecules 
or with Gs in other RNA molecules, decreasing the efficient exposure of each cytosine to 
bisulfite mix. We also noticed that even in extended exposure times, for RNAs capable of 










Figure 2.1 | HPLC chromatogram of Cytidine (C) and 5-methyl-cytidine (m5C) nucleosides 
before and after sodium bisulfite treatment. a, The schematics of the effect of bisulfite ions on 
specific deamination of cytidine and 5-methyl-cytidine nucleosides. b, HPLC chromatograms 
showing the kinetics of bisulfite treatment on C and m5C nucleosides. Blue lines show the non-
treated samples and purple lines show the bisulfite treated samples for 1.5 hrs at 50οC. The 2’-








Figure 2.2 | Schematic representation of the bisulfite sequencing results of the linear and 
structured RNA oligonucleotides in different conditions and the effect of formamide. a, 
Bisulfite sequencing results of the three different conditions tested on linear nonmethylated 
(left) and methylated (right) synthetic RNA oligonucleotides. b, Bisulfite sequencing results of 
the two different conditions tested on structured nonmethylated (left) and methylated (right) 
synthetic RNA oligonucleotides. c, sequence of the linear 60bp and structured 70bp RNA used in 
this experiment. The regions between the dotted lines show the readable regions after 
sequencing. (The 5’ and 3’ sides have been used as the primer binding site for bisulfite specific 
PCR primer sets for amplification of the bisulfite treated RNAs.) Arrowheads show the place of 
the methylated cytosine in the methylated oligonucleotides. d, Summary of the bisulfite 
conversion efficiencies obtained in the different conditions tested in (a) and (b). Note that there 
is always some background level m5C to U conversion.  
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To solve this incomplete conversion rate and also increase the recovery yield we used 
formamide, a strong denaturing reagent, in the mixture. 
In this new procedure we used 100% deionized formamide (final concentration of 84%) 
to denature the highly structured RNA molecules at elevated temperatures (75-95οC) and also 
kept the formamide during the bisulfite treatment, at 40% final concentration, to both 
protecting the RNA molecules from degradation and preventing the denatured secondary 
structures from reformation, for efficient conversion. Using this recipe we were able to extend 
the treatment time to 16 hours at 50οC to get the 100% conversion efficiency and about 50-60% 
recovery rate (Figure 2.2). Next we tested this on small and large RNA fractions isolated from 
cultured cells. For the small RNA fraction we got comparable conversion efficiency (confirmed 
by high-throughput sequencing) and recovery rate. However, for the large RNA fraction our 
initial experiments with the intact total RNA failed to return enough uniform RNA for library 
preparation (Figure 2.3).  
To test whether the fragment size will affect the recovery yield, we fragmented the 
HeLa cells’ total RNA into fragments of about 60-200bp using RNA fragmentation reagent 
(Ambion), and subjected it to bisulfite treatment. Surprisingly this resulted in uniform RNA 
population, and recovery yield comparable to the small RNA fraction (Figure 2.3). Interestingly 
fragmentation of RNA prior to bisulfite treatment may also have some other advantages (see 
discussion).  
 
High-throughput RNA bisulfite sequencing of MEFs samples 
After testing the modified RNA bisulfite sequencing method with synthetic 








Figure 2.3 | Effect of RNA fragmentation on the recovery yield and uniformity of the fragment 
sizes after bisulfite treatment. Bioanalyzer results show that bisulfite treatment of the small 
RNA and fragmented large RNA samples produces uniform population of fragment sizes and 
better recovery yield, while bisulfite treatment of the intact total RNA results in severe 
degradation making a mixed population of different fragment sizes with lower recovery yield. 
The Y axis is the fluorescent unite (FU) and the X axis shows the retention time of each individual 
fragment in seconds (correlating to its length). This experiment has been done in the presence 
of formamide. 
No treatment Bisulfite treatment               
(+ formamide) 
a. Total RNA 
c. Fragmented  
    large RNA 
b. Isolated  
     small RNA 
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 the parameters on total RNAs extracted from the cells, we applied the technique on RNA 
samples extracted from mouse embryonic fibroblasts (MEFs) isolated from wild-type (WT) or 
Dnmt2 null mice. We chose MEFs for their availability and also because that they represent a 
single cell type. Thus, they are preferred over using a tissue, as this will help in reducing the 
complexity of the transcriptome and increasing the resolution and coverage of sequencing 
especially over expected low-copy transcripts.  
MEFs were separately isolated from day 13.5 isogenic embryos from either of wild-type 
(B6129PF2/J) or Dnmt2-/- (B6;129-Trdmt1tm1Bes/J) 14 mice. After passaging for several days, MEFs 
were harvested and subjected to RNA purification and DNase treatment to remove DNA 
contaminants. Part of the RNA samples were used for small RNA preparation using MirVana kit 
(Ambion) and the rest were subjected to ribosomal RNA depletion via Ribominus kit 
(Invitrogen). The ribosomal RNA deplete fractions were then subjected to chemical 
fragmentation to yield fragments of 60-200bp sizes. Each of the small and fragmented large RNA 
fractions from each of WT or Dnmt2-/- MEFs were split into two equal portions: one for direct 
RNA sequencing and one for RNA bisulfite sequencing. A total of eight samples were then used 
each separately for library preparation and 101-single end sequencing, each sample on one lane 
with Illumina’s HighSeq-2000. A flowchart representing multiple steps of our high-throughput 
RNA bisulfite sequencing protocol is provided in Figure 2.4. We sequenced the nonbisulfite 
treated samples because in our pilot experiments we noticed that after bisulfite sequencing and 
mapping some small RNAs mapped to some regions of the genome (including coding and repeat 
regions) even though the surrounding regions in many cases did not show any mapped reads. 
We considered this as an indication of mapping errors happening due to lower base composition 







Figure 2.4 | High-throughput RNA bisulfite sequencing flowchart. This flowchart shows the 
stepwise procedure of high-throughput RNA bisulfite sequencing. See text for details.   
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mapping due to C>T conversions. Implementing this allowed us to avoid misannotation of the 
sequencing reads, and introduction of false positives. To remove these artifacts we sequenced 
the nonbisulfite treated portions of each one of the samples separately and used them as a 
mapping control at the time of analysis. The assumption is that if a bisulfite treated RNA is 
mapped to a specific location of the genome, the same location should show some sequencing 
read coverage in the nonbisulfite treated sample as well. In another word, those reads that are 
only present in the bisulfite treated but not in the corresponding nonbisulfite treated datasets 
are most likely due to mapping errors (acquired mapping artifacts) and should not be considered 
true sequencing reads when calling the methylation sites.  
 
Developing an analysis pipeline for RNA bisulfite sequencing datasets 
To facilitate the identification of candidate m5C sites in the bisulfite treated RNA 
datasets we developed an analysis pipeline summarized in Figure 2.5. The commercial Novoalign 
package (http://www.novocraft.com) was used to align the sequencing datasets from each one 
of the eight MEF RNA samples (Bisulfite (BS) or nonbisulfite (NBS), Small or large RNAs, from wt 
or dnmt2-/-) to the mouse transcriptome index files. First two separate transcriptome index 
files, normal (nonbisulfite converted) and bisulfite converted, were made using “Novoindex 
application” from Novoalign package. To make the Novoindex files, the entire genome 
sequences (from all chromosomes) from M. musculus July 2007 (NCBI37/mm9) genome build 
was used. In addition to include all known and theoretical splicing events, the 
“MakeTranscriptome” application from open source USeq package15 was used to extract, and 
include, all known and theoretical splice junctions derived from Ensembl transcripts from the 












Figure 2.5 | RNA methylation analysis pipeline. This flowchart shows the bioinformatics 
analysis steps for finding the candidate methylated sites in the transcriptome. See text for 




from the Novoalign package, with options to allow gaps and mismatches, reporting 18bp or 
larger inserts, and reporting all of the reads mapped to the repeats. The nonbisulfite treated 
datasets were aligned to the normal transcriptome indexed file, and alignment output files were 
generated in the SAM format. The bisulfite treated datasets were aligned to the transcriptome 
indexed file generated in the bisulfite mode, and alignment output files were generated in both 
the SAM and Pairwise formats. To visualize the sequencing reads the SAM-formatted alignment 
files of the bisulfite treated or untreated datasets were processed by the “RNASeq” application 
of the USeq package to make the BAM/BAI files. The BAM/BAI files were then used to inspect 
the sequencing reads at base pair resolution using the Integrative Genomics Viewer (IGV).16 
Pairwise-formatted alignment files were processed by custom python scripts to call, annotate 
and make the tables of candidate methylated cytosines. Custom Perl scripts were used to filter 
the methylation tables (read coverage ≥ 10 and nonconversion rate ≥ 20 % in any of the 
datasets).  
To find the Dnmt2 target sites the candidate methylation table was filtered again to 
keep only sites showing significant methylation in wt but not in dnmt2-/- datasets.  The 
candidate sites were then verified by manual inspection of the individual mapped reads, by 
filtering out the sites showing coverage only in the bisulfite treated (but not the untreated) 
datasets (an example is provided in Figure 2.6) due to mapping errors caused by lowered base 
composition complexity of the reads in the bisulfite treated samples. Further inspections were 
performed to remove the aggregated candidate sites showing clusters of non-converted Cs in 
the bisulfite treated datasets. To lower the rate of false positives we removed such sites from 








Figure 2.6 | An example of methylated sequenced reads mapped to a SINE repeat with no 
reads mapped to the same region in the nonbisulfite treated dataset. A random IGV snapshot 
from a subset of reads mapped to a SINE element.  Although in the bisulfite treated datasets 
(top panel) the mapped reads show significant methylation in a single site, because of the lack 
of corresponding mapped reads in the nonbisulfite treated datasets (lower panel) this will be 
considered a mapping error and the corresponding candidate site will be removed from the list 




Figure 2.7 | An example of clustered nonconverted cytosines in the reads mapped to an rRNA 
locus. A random IGV snapshot from a subset of reads mapped to an rRNA. The region shows a 
high GC content. Several nonconverted cytosines in the bisulfite treated dataset (top), in this 
high GC rich region of the genome, indicate a possible artifact but not true methylation sites. 
The lower panel shows the nonbisulfite treated dataset. Only the wt datasets shown as both wt 
and dnmt2-/- are similar. 
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The MEFs RNA methylome 
Alignment of the sequenced reads from bisulfite treated and nontreated, small and 
large RNAs from wt and dnmt2-/- samples revealed 90 to 100 million mapped filtered reads per 
dataset. The small and large RNA datasets from the bisulfite treated samples were combined for 
methylation analysis. The row methylation analysis of the wt and dnmt2-/- MEFs datasets 
combined revealed about 99% conversion efficiency with a consistent pattern between the two 
types of datasets (wt and dnmt2-/-)  in all non-Dnmt2 target genes. Figure 2.8 shows the 
reproducibility of the applied RNA bisulfite sequencing approach by showing the consistency in 
both of the exact sites and also in their conversion levels for the panel of rRNA genes.  Analysis 
of both wt and dnmt2-/- MEFs datasets, collectively, considering the cutoff of >10 read coverage 
and >20% nonconversion rate at the sites in either or both of the datasets, revealed a list of 
13,520 candidate m5C sites in the MEFs transcriptome. However, after visual inspection of the 
mapped sequencing reads in IGV (to filter the table by removing the sites showing sequence 
coverage only in the BS but not NBS datasets, and also removing the sites showing clustered 
non-conversions), about 90% of the sites were identified as artifacts, shortening the list of 
candidate sites to 1305 verified sites (Figure 2.9). It is important to mention that the level of 
methylation at each particular candidate site was different (i.e. highly, moderately or weakly 
methylated) (Figures 2.10 and 2.11).  As expected most of the candidate sites were mapped to 
tRNAs as most eukaryotic tRNAs bear one or more m5C sites in their structures. A lower number 
of candidate sites were found in rRNAs, snRNAs and scRNAs, and two other ncRNAs; 
ribonuclease P RNA (Rpph1) and ribonuclease P RNA-like 1 (Rprl1).   Surprisingly, protein coding 
transcripts (mRNAs) showed a high number of candidate sites (total of 388 sites). These sites 










Figure 2.8 | An example of a consistent pattern of nonconverted Cs in the rRNA transcripts. 
The individual scatter plots of nonconversion levels are presented here showing the pattern of 
nonconverted Cs and their nonconversion levels in both of the wild type (wt) dataset at top and 
dnmt2 null (dnmt2-/-) dataset at bottom. The Y axis shows the nonconversion levels (%) and the 
X axis shows the position of individual Cs in each rRNA transcript. The bisulfite (BS) datasets of 
each sample (wt and dnmt2-/-) were separately aligned to an index file generated from an 
artificial transcriptome containing the standard mouse rRNA sequences (18S, 28S, 5.8 and 5S 
rRNA genes) obtained from gene bank. The level of conversion at each cytosine base in each of 
the four rRNA genes were then calculated with custom python scripts and plotted in Excel. 
Comparison of the nonconversion patterns in two datasets clearly shows a consistent trend for 
both of the exact sites and also the nonconversion levels, indicating the reproducibility of the 
results with the established high-throughput RNA bisulfite sequencing method. Note the 
observed sites with some levels of nonconversion are not necessarily true m5C sites and further 
filtering steps (explained in the text) are required for defining the most probable candidate m5C 
sites.  
18S rRNA (wt) 28S rRNA (wt) 5.8S rRNA (wt) 5S rRNA (wt) 























Figure 2.9 | Distribution of candidate m5C sites in annotated coding and noncoding genes, and 
repeats. The pie graphs show the distribution of annotated candidate m5C sites identified in 
either of the wt or dnmt2-/- datasets under different categories: a, coding genes, b, ncRNAs, and 




Figure 2.10 | An example of a highly methylated site. A random IGV snapshot from a subset of 
reads mapped to the 3’-UTR region of hepatoma-derived growth factor (Hdgf) gene. This site 
shows a high degree of methylation at position chr3: 87718567. The top panel shows the 
sequencing reads from bisulfite treated RNAs (BS) and the bottom panel shows the sequencing 
reads from nonbisulfite treated samples (NBS). Only the wt datasets shown as both wt and 









Figure 2.11 | An example of a low/moderately methylated site. A random IGV snapshot from a 
subset of reads mapped to the coding region of KDEL (Lys-Asp-Glu-Leu) containing 2 protein 
(Kdelc2) gene. This site shows low to moderate degree of methylation at position 
chr9:53198635. The top panel shows the sequencing reads from bisulfite treated RNAs (BS) and 
the bottom panel shows the sequencing reads from nonbisulfite treated samples (NBS). Only the 
wt datasets shown as both wt and dnmt2-/- are similar. 
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the reads mapped to the intronic regions or to 5’-UTR of the genes. The methylation report for 
the candidate m5C sites within the protein coding genes is provided in Supplementary Table S1 
in Appendix A. Most genes show only a single significant candidate m5C site in their mRNAs; 
however there were also a few genes with more than one site (Supplementary Table S1 in 
Appendix A).  The gene ontology (GO term) analysis of the genes showing m5C sites, using the 
web-based GoMiner application17 showed enrichment of genes in diverse cellular processes, 
with “metabolic” and “regulative-related” processes and pathways at the top of the list (Table 
2.2). Regarding the sites mapped to the repeat regions quite a high number of sites were 
identified in LTR retrotransposons, while only few candidate sites were found in LINE, SINE, or 
other repeat families (Figure 2.9). Notably, almost all of the candidate m5C sites in LTRs were 
from short sequences related to the tRNA binding sites of the endogenous retroviruses (ERVs) 
(an example in Figure 2.12). ERVs, like retroviruses, bear tRNA binding sites in their structures as 
they rely on tRNA binding for their replication.  Because the surrounding regions of tRNA binding 
sites were devoid of any mapped reads in the datasets (an example in Figure 2.12), it is most 
likely that the methylated mapped reads are not derived from the LTRs. They are most likely 
tRNA fragments which can map to the tRNA binding sites of the LTRs. We note that this is not 
specific to the methylated tRNA fragments as for many of the other annotated LTRs, 
unmethylated reads were observed, most likely derived from unmethylated tRNAs or the 
unmethylated portions of the methylated tRNAs.  
 
Dnmt2 targets in MEFs 
        DNA methyltransferase 2 (DNMT2) which is present in most eukaryotic organisms was first 








Table 2.2: Gene Ontology (GO) term analysis of the protein coding genes showing cytosine 
methylation sites 
 





1 GO:0009987_cellular_process 12158 156 1.895199 -22.99383 
2 GO:0008152_metabolic_process 8152 117 2.119894 -18.287889 
3 GO:0044238_primary_metabolic_process 7002 105 2.214928 -17.141621 
4 GO:0044237_cellular_metabolic_process 6932 103 2.194679 -16.419523 
5 GO:0019538_protein_metabolic_process 2926 58 2.927831 -13.338066 
6 GO:0043170_macromolecule_metabolic_process 5745 84 2.159641 -12.29361 
7 GO:0048519_negative_regulation_of_biological_process 2292 48 3.093278 -11.761033 
8 GO:0044260_cellular_macromolecule_metabolic_process 5139 77 2.213117 -11.621887 
9 GO:0048523_negative_regulation_of_cellular_process 2098 45 3.168104 -11.350529 
10 GO:0044267_cellular_protein_metabolic_process 2443 49 2.962545 -11.336859 
11 GO:0016043_cellular_component_organization 2858 53 2.739088 -11.003136 
12 GO:0071840_cellular_component_organization_or_biogenesis 2975 54 2.681014 -10.866587 
13 GO:0051179_localization 3440 58 2.490359 -10.433511 
14 GO:0006810_transport 2862 49 2.528825 -8.95405 
15 GO:0008219_cell_death 1294 31 3.538505 -8.952245 
16 GO:0016265_death 1302 31 3.516763 -8.888556 
17 GO:0051234_establishment_of_localization 2898 49 2.497411 -8.773695 
18 GO:0065007_biological_regulation 7925 94 1.751947 -8.731596 
19 GO:0048518_positive_regulation_of_biological_process 2632 46 2.581454 -8.6713 





Figure 2.12 | An example of methylated sequenced reads mapped to an LTR. A random IGV 
snapshot from a subset of reads mapped to an LTR repeat region (LTR-ERV1-MuLV-int). Three 
sites in the bisulfite treated (BS) panel (top) show methylation. Also in the nonbisulfite treated 
panel we have sequencing reads mapped to the same region. This indicates that the methylation 
events are more likely real. However, the sequencing reads are less likely to be driven from the 
LTR although they can map to it. This is because the surrounding regions do not show any 
mapped reads and also the reads are mapped to the tRNA binding site of the LTR 
retrotransposon.  Only the wt datasets shown as both wt and dnmt2-/- are similar. 
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widely conserved DNMT enzyme within eukaryotes, which has all of the required motifs for 
methyltransferase activity, and its catalytic domain resembles the methyltransferase domain of 
other active DNMTs, DNMT1 and 3.18 However, more than a decade of efforts to prove the DNA 
methyltransferase activity for this enzyme resulted in finding that DNMT2 is actually not a DNA 
methyltransferase but rather is an RNA methyltransferase instead.14, 19-21 The first RNA substrate 
recognized for DNMT2 was tRNAAsp in several organisms and the exact target residue mapped to 
C38 in the anticodon stem-loop of the tRNA structure.14, 19, 20 Most organisms lacking DNMT2 
lack obvious phenotype,18 although Dnmt2 morphant zebrafish shows developmental 
perturbations,19 however, the high degree of sequence and structural conservation of DNMT2 
between divergent organisms prompts more thorough analysis to find its other targets and 
eventually its functions for the organisms.18, 22  Since the discovery of RNA methyltransferase 
activity of DNMT2, only two target sites (C38 in tRNAGly and tRNAVal) were found as other targets 
of the enzymes.11 There is currently no transcriptome-wide comparative RNA methylome report 
comparing the wt and dnmt2-/- null RNA methylomes to find the enzyme’s other possible 
targets in a broader pool of RNA molecules. Here, as the first comprehensive analysis of its type, 
comparison of the entire wt and Dnmt2-/- MEFs RNA methylomes followed by filtering the false 
positive m5C calls revealed that C38 in known DNMT2 tRNA targets (tRNAAsp, tRNAGly and 
tRNAVal) are completely unmethylated in Dnmt2-/- datasets while they show significant 
methylation at the exact same sites in wt datasets. Beside these we did not detect any other 
differentially methylated site in the entire transcriptome. This clearly demonstrates that in 
MEFs, at normal conditions, exclusively C38 sites of these three tRNAs are the DNMT2 targets 










Figure 2.13 | tRNA methylation patterns in known Dnmt2 tRNA targets. The bar graphs show 
the methylation levels at each cytosine base within the three known Dnmt2 tRNA targets in both 
of wt (blue) and dnmt2-/- (red) datasets.  There are methylation sites in each tRNA which are 
not the Dnmt2 target sites which show methylated at similar levels in two datasets. The Y axis 
shows the methylation levels (%) and the X axis shows the position of individual nucleotides (Cs) 
in each rRNA transcript. The bisulfite (BS) datasets of each sample (wt and dnmt2-/-) were 
separately aligned to an index file generated from an artificial transcriptome containing only the 
standard mouse tRNA sequences obtained from genomic tRNA database 
(http://gtrnadb.ucsc.edu). The methylation levels at each cytosine base in each tRNA were then 
calculated with custom python scripts and plotted in Excel (here only three tRNAs are shown). 
Comparison of the methylation patterns in two datasets clearly shows that C38 in tRNAAsp, 
tRNAVal and tRNAGly are the only known targets of Dnmt2. Note that we did not detect any other 




In this report we presented a new efficient RNA bisulfite sequencing protocol suitable 
for high-through transcriptome-wide RNA methylation profiling. To obtain this protocol we 
systematically tested different parameters at multiple levels including nucleoside, synthetic 
methylated/unmethyalted, and linear/structured RNA oligonucleotides and eventually total 
RNA, to formulate the protocol. In this approach, we introduced formamide into the mixture for 
two main purposes: 1) to denature the local RNA secondary structures in the denaturation and 
sulfonation steps for efficient conversion, and 2) to protect the RNA from degradation during 
the procedure to increase the recovery yield.  
For efficient methylation profiling in long RNA species we used RNA fragmentation prior 
to bisulfite treatment. Fragmentation has several advantages. First, RNA fragmentation disrupts 
the secondary structures within the large RNA molecules, and thus improves the conversion 
efficiency to great extents. Second, because the fragmentation is a random process, breaking 
RNA molecules at different locations, it could potentially help to distinguish the true 
methylation sites from the artifacts produced by extremely strong secondary structures. Third, 
bisulfite treatment of the fragmented large RNA, after recovery, shows a uniform population of 
converted RNA molecules suitable for library preparation while the same treatment on non-
fragmented total RNA resulted in drastic degradation and a mixed population of different 
fragment sizes.  
To filter out the false positives due to possible mapping errors, as the result of the 
decreased base composition complexity in the bisulfite treated RNA sequences we sequenced 
the non-bisulfite treated samples with the logic that a mapping event is only valid if a particular 
genomic region contains mapped sequenced reads in both of the bisulfite treated and non-
treated datasets.  
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Our results proved that we have formulated an efficient and reproducible RNA bisulfite 
sequencing approach with about 99% conversion efficiency of the unmethylated cytosines. Due 
to some extremely strong secondary structures in some RNA molecules we did not expect a 
complete 100% conversion efficiency. The sites with more probable nonconversion rates are 
somehow predictable and most of them are expected to reside in the GC rich regions with 
adjacent palindrome sequences increasing the likelihood of strong secondary structure 
formation. Such structured hairpin-loops might even be strong enough to resist denaturation in 
the presence of formamide at high temperatures. The undenatured regions of the RNA 
molecules will produce incomplete conversion and are the major source of false positives in RNA 
bisulfite analysis. In order to resolve this, during the analysis, we removed the aggregated 
nonconverted cytosines appearing in clusters in highly GC reach regions by visual inspection of 
the sequencing reads. Candidate sites falling in such clustered nonconverted regions were then 
removed from the initial list. This helps to narrow down the table of candidate m5C sites to a 
shorter list with higher confidence level to call the true methylation sites.  
It is important to note that the low copy number of most RNA species, as well as the low 
methylation penetration at particular sites, will decrease the chance of detecting all possible 
m5C sites within the transcriptome and always some false negatives are expected. In addition, 
the stringent filtering parameters we have considered in our analysis, although providing more 
accurate list of candidate m5C sites, can cause missing some of the true m5C sites as well 
producing some false negatives. To overcome the issues with low copy number RNA species or 
low methylation penetration the enrichment protocols can be used13 (see Chapter 3). Also 
application of emerging single molecule RNA sequencing technologies capable of direct 
detection of nucleotide modifications23 (see Chapter 4) might help identify some other true m5C 
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sites which may have been filtered as they appear in highly structured regions showing non-
converted  cytosines in their neighborhood.  
Regarding the DNMT2 target identification, we showed that C38 in the stem-loop 
junction of the anticodon loop of tRNAAsp, tRNAGly and tRNAVal are the only targets of Dnmt2 
enzyme in MEFs at normal conditions. This, however, does not rule out the possibility of DNMT2 
to methylate other RNA targets, in other cell types or tissues and at other conditions such as in 
stress or immune response. Especially, Dnmt2 has been shown to be required for efficient 
control of RNA viruses in Drosophila Melanogaster.24 Limited RNA bisulfite sequencing analysis 
showed that pmt1, the human DNMT2 homolog in fission yeast, is getting activated upon 
nutrition deprivation resulting in significant increase at the methylation level of C38 in tRNAAsp. 
Interestingly this process is under the control of the serine/threonine kinase Sck2 arm of the 
yeast nutrient signaling pathways.25  
Dnmt2 has been shown to be responsible for retrotransposon silencing in Drosophila 
somatic cells26 and a recent report indicates that during stem-cell division Dnmt2 is required for 
chromosome-specific nonrandom segregation of the sister chromatids through a yet to be 
known mechanism.27 Since comprehensive DNA methylation analysis demonstrates that DNMT2 
has no detectable DNA methyltransferase activity,21, 28 it is tempting to speculate that the 
aforementioned observed functions are purely due to the RNA methyltransferase activity of 
DNMT2.  If this is true, two scenarios may be considered: 1) DNMT2 is a pure tRNA 
methyltransferase and methylated tRNAs or methylated tRNA fragments role in such processes, 
or 2) DNMT2 can methylate other RNA targets and they are responsible for the observed 
phenotypes. Although several reports indicate that DNMT2 is a highly specialized tRNA 
methyltransferase enzyme recognizing a specific cytosine in the CpG context and at the exact 
stem-loop junction of specific tRNAs in several species, it is possible that it recognizes tRNA-like 
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structures within other RNA species.13, 29 We have recently reported that human DNMT2 can 
methylate a cytosine, resembling the DNMT2 target site, within a tRNA-like structure in KRT18 
mRNA at very low levels.13 It is, however, not clear whether DNMT2 can methylate this or similar 
sites in other RNAs at biologically relevant levels in special conditions. Overall, a comprehensive 
RNA methylome profiling in wt and DNMT2 null organisms in different cell types or conditions 
seems to be required to reveal the other possible RNA targets of this enzyme.  
Regarding the MEFs methylome in this report, our transcriptome-wide methylation 
profiling showed that in MEFs at normal conditions, tRNAs and mRNAs are the most frequent 
targets of RNA cytosine methylation in comparison to other RNA species. It is important to note 
that quantification of the bulk m5C contents in total RNA by chromatography and mass-
spectrometry approaches (LC-MS), clearly shows that most of the bulk m5C contents are coming 
from tRNAs.29 This has two reasons: first tRNAs are highly modified as most of the eukaryotic 
tRNAs, in their short transcripts of about 75pb on average, bear one or more m5C sites, and 
second tRNAs are extremely abundant in comparison to most RNA species including mRNAs but 
not rRNAs. This is evident in organisms lacking the two major tRNA cytosine methyltransferases, 
DNMT2 and NSUN2, in which the bulk m5C level in RNA is dropping to close to the background 
level.29 Therefore, the m5C levels in non-tRNA species specifically in mRNAs are considered to 
make a very small portion of the bulk m5C content of total RNAs, due to low copy number of the 
RNAs and scarcity of the sites within the long RNA molecules. However, it is highly interesting to 
explore the exact functions of such methylated sites.  
High-throughput mapping of few RNA modifications such as N6-methyladenosine (m6A) 
and C to U editing events showed significant enrichment in the 3’-UTR of mRNAs.30-32 We have 
also found many m5C sites in the 3’-UTR of mRNAs. Concentration of modified nucleotides 
within the untranslated regions can be linked to regulation of processes such as mRNA export, 
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localization and translation as both 5’- and 3’-UTRs are enriched in regulatory elements. 
However, unlike previously reported RNA cytosine methylome in HeLa cells claiming that 
majority of m5C sites are concentrated within the 3’-UTR of mRNAs,12 we identified a 
comparable number of candidate m5C sites within the coding regions too. It is therefore 
interesting to speculate possible functions for such sites within the protein coding segments of 
the mRNAs.  
DNMT2 and NSUN2 are believed to be responsible for methylating all of the known sites 
within tRNA genes.13 There are at least 8 other RNA cytosine methyltransferases (m5C-RMTs) in 
human genome, which are believed to be responsible for methylation of most of non-tRNA 
sites.8 Disruption or misregulation of some of these genes are linked to genetic disorders, 
infertility and cancer8  and it is therefore interesting to look at their exact direct target 
molecules/sites as well as their functions in the cells.  
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IDENTIFICATION OF DIRECT TARGETS AND MODIFIED  








































DISCOVERING THE EPITRANSCRIPTOME: POTENTIALS,  





Natural nucleic acid polymers are made of only four standard nucleotides: A, C, G and 
T/U in DNA/RNA. However, after replication and transcription some of the incorporated 
standard nucleotides, at specific positions, undergo chemical changes to produce “modified 
nucleotides,” in both DNA and RNA.   
The first modified nucleotide, m5C, was identified in 1948 in genomic DNA.1 Since then, 
however, only a few other modified nucleotides have been characterized in DNA, which can be 
categorized under two groups. The first group is composed of those wanted events, which are 
made enzymatically such as hm5C, f5C, ca5C, m6A and Base J.2 These are generated on purpose 
and have substantial known, or to be known, functions. Members of the second group are those 
unwanted events, which are produced as the result of DNA damage upon chemical or UV 
exposure, such as 8-oxo-A, Xanthine, Inosine etc., known as DNA lesions2. Cells have adopted 
elaborated pathways to actively and selectively recognize and replace these with normal 
nucleotides to prevent interruptions and errors during replication. Overall, it is evident that 
accommodation of natural modified nucleotides in genomic DNA has been restricted to very few 
instances during evolution, more likely to avoid compromising the processivity and fidelity of 
replication and transcription processes. This is because that some modifications can pause or 
slow down DNA/RNA polymerases, on DNA, and some others can affect the standard A:T, C:G 
base paring rules and therefore compromise the maintenance and flow of genetics information.  
RNA, in contrast, does not serve as the genetic repertoire of living organisms, except in a 
few viral examples, and once is transcribed it will no longer be used as polymerization template, 
except in a few examples of RNAs involved in telomere maintenance or propagation of infective 
retroviruses and retrotransposons. Thus there has been no evolutionary pressure to prevent the 
standard nucleotides of RNA molecules from being evolved into new modified entities. In 
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addition unlike the single function of DNA, the genetic reservoir, RNAs have become specialized 
for more diverse responsibilities in living organisms, which partly explains their greater tendency 
to accommodate much more modified nucleotides, something over 100 distinct structures, 
characterized so far.  
RNA modification can be defined as any post-transcriptional alteration of the structure 
of standard nucleotides within the RNA polymers once they are being transcribed. According to 
this definition from simple deamination and editing of C to U bases in mRNAs to the formation 
of the hypermodified wybutosine (yW) in the anticodon of eukaryotic phenylalanine tRNAs are 
considered RNA modifications. Generation of almost all modified nucleotides (except for few 
that are produced upon RNA damage) is enzymatic requiring one or more specialized enzymes 
depending on the reactions. In addition the modification processes often take place within 
complexes composed of one or more accessory proteins and/or RNAs, each with specific roles 
such as providing the scaffold for the modification complex or guiding the modifier enzymes to 
specific RNA and/or specific nucleotide targets.  
In principle, all accessible portions of a given nucleotide, base, sugar and phosphate, can 
become targeted by RNA modifier enzymes (Figure 4.1).  Although sugar and phosphate 
modification types are limited (Figure 4.1a,b), the base modification is highly diverse, which is 
achieved through one of the four reaction types: functional group substitution, or addition, and 
base exchange, or isomerization (Figure 4.1c). All these modifications together shape the cellular 







Figure 4.1 | Classification of RNA nucleotide modifications. a, Sugar modifications. There are 
few types of sugar modifications. Here a single 2’-O-methylated nucleotide (Nm) as part of an 
RNA molecule is shown with a methyl group at the 2’ position of the sugar. The “Base” can be 
any of A, C, G or U. b, Phosphate modifications. There are few types of phosphate modifications. 
Here a 5’-γ-methylphosphate capped RNA is shown. c, Base modifications. There are over 100 
distinct enzymatically made base modifications in RNA. Most base modifications are made 
through either functional group substitution or addition. Limited modifications are generated 




Modified nucleotides are present, in different frequencies, in both coding and non-
coding RNA molecules of different types. Modified nucleotides function in regulating the mRNA 
processing and translation, or affect their stability and turnover rates. They can also provide 
additional letters to RNA alphabet or redefine the open reading frames (ORFs) increasing the 
coding capacity of mRNAs. In noncoding RNAs (ncRNAs) modifications provide new structural 
and functional features, expanding the flexibility and operative capabilities of diverse ncRNAs 
serving as transfer, catalytic, structural, regulatory or guide RNAs (Figure 4.2). Here, to 
emphasize on the importance of RNA modification research, we briefly introduce some selected 
modified nucleotides that have been studied more in the past. 
N7-methylguanosine (m7G) is the most studied modified nucleotide in mRNAs as it is the 
main component of the eukaryotic mRNA 5’-cap structure.3  5’-cap is made by addition of a non-
templated guanosine to the 5’ end of mRNAs through formation of an unusual 5' to 5' 
triphosphate linkage followed by enzymatic methylation of G at position N7. It functions in 
regulation of mRNA stability, splicing, transport, and translation.4 5’-cap structure has also been 
found at 5’ end of some noncoding RNAs including a subset of small RNAs, in which its function 
is yet to be explored.5 Internal m7G is also widely present in both prokaryotic and eukaryotic 
tRNAs.6  
N6-methyladenosine (m6A) is probably the most abundant internal modification in 
eukaryotic mRNAs from yeast to human, and is also present in their tRNAs, rRNAs and snRNAs, 
as well as in bacterial and archeal tRNAs and rRNAs and some viral RNAs.7 In Saccharomyces 
cerevisiae, meiotic mRNAs show much higher m6A levels as compared to mitotic mRNAs, and 
m6A content of polyA RNA fraction shows remarkable increase upon induction of sporulation. 






Figure 4.2 | Functional classification of RNA modifications. a, Modifications affecting the 
coding information of mRNAs. Some post-transcriptional modifications within the open reading 
frames (ORFs) can change the way the triplets are decoded in the ribosomes introducing a 
different amino acid and changing the protein sequence. Nucleotide modifications can also 
change the definition of ORFs to produce shorter or longer protein chains through introduction 
of new or removal of the existing start/stop codons. b, Modifications affecting the structure or 
functions of decoding (translation) machinery. tRNAs and rRNAs are the most highly modified 
RNA species and the modifications are required for their proper folding and activity. Both the 
rate and fidelity of translation can be changed by changes in tRNA or rRNA modifications. c, 
Modification assisted folding. Some RNA molecules require nucleotide modifications to obtain 
their proper folding.  d, Modification induced conformational changes. Nucleotide modifications 
might help switching the conformation of a folded RNA from one state to the other. e. 
Modifications affecting the interactions. Nucleotide modifications can provide new structural 
properties for RNAs to absorb or repel specific proteins binders. The binders might prefer 
binding to either of the modified or unmodified RNAs. Here protein-RNA interaction is shown, 
but in general nucleotide modifications might affect other interactions as well as interaction of 
RNA with DNA, RNA, small molecules, ions, etc. f. Modifications affecting the catalytic activity of 
the ribozymes. It is anticipated that nucleotide modifications in ribozymes affect their substrate 
specificity or catalytic activity for specific RNA substrates. g. Modifications affecting the RNA 
stability (turnover rates). Modifications can prevent degradation of RNAs. Examples are mRNA 
5’-capping and changing the miRNA binding sites of mRNAs through RNA editing. There may also 





cell fate control and initiation of meiosis in budding yeast.8, 9 m6A contents in Arabidopsis 
thaliana is tissue specific with higher levels in flower buds in comparison to leaves and roots.10 
N6-adenosine methyltransferase gene (MTA) is required for normal growth and organ definition 
as well as prompt and proper responses to environmental stresses and stimuli in plants.11 This 
modification is also essential for development and gametogenesis of drosophila melanogaster 
and complete deletion of the methyltransferase gene (Dm ime4) is lethal for the organism.12 
m6A was known for years to be present in mammalian mRNAs, with only one mapped m6A in 
bovine prolactin (bPRL) mRNA.13 Recently two transcriptome-wide profiling of this methyl mark 
in human and mouse cells revealed a widespread occurrence of this modification in both coding  
and noncoding RNAs (more than 12,000 sites). Many of these sites were shown to be 
evolutionary conserved between human and mouse, with more incidents around the stop 
codons and within the long internal exons.14, 15  
Conserved locations in tRNAs and rRNAs contain 5-methylcytosine (m5C) and a recent 
study shows the widespread occurrence of cytosine methylation in other noncoding RNAs and 
also in many mRNAs.16, 17 Although the exact function of cytosine methylation is still unknown, 
gene disruption or miss-regulation of some known cytosine methyltransferases can result in 
variety of different abnormalities such as developmental defects, mental retardation, infertility, 
growth problems and cancer.16, 18-26 In addition, recent works by several groups suggest that the 
main functions of cytosine methylation could be more involved during the stress conditions 
and/or in cellular response to pathological conditions such as in defense against the infective 
RNA viruses.27-29  
Inosine (I) is another widespread modified nucleotide produced upon deamination of 
adenosine by adenosine deaminase enzymes, in a process known as RNA editing. Because I 
prefers to base pair with C (instead of U), A to I editing changes the sequence information of 
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mRNAs, post-transcriptionally. Editing within the open reading frame (ORF) can then change the 
transcribed codes and produce new protein isoforms and contribute in functional diversification 
of the proteome. Indeed possible edition of the adenosine residues may result in generation or 
removal of the start (AUG) or stop (UGA, UAG, UAA) codons, redefining the ORFs in the edited 
mRNAs.  ORF extension as the result of changing non-sense to sense codon upon adenosine 
deamination has been reported for viral RNAs.30 A recent transcriptome-wide profiling of the 
edited sites in human, however, shows that in mRNAs, A to I editing events are more frequent in 
3’ UTRs and introns and moderately abundant in 5’ UTRs. Although the exact contribution of 
majority of these events are not known, some of the edited sites in 3’UTRs were mapped to the 
miRNA binding sites suggesting the regulatory roles of this process. A number of edited sites in 
small and long noncoding RNAs have also been reported including some that happen within 
miRNA precursors affecting their biogenesis.  
The C to U transition through post-transcriptional deamination of cytosines is another 
way of changing the coding information of mRNAs. This is very well documented in the case of 
APOBEC1 mediated mRNA editing, generating new in-frame stop codons in apolipoprotein B and 
neurofibromin-1 mRNAs to produce shorter forms of the proteins in special cases or tissues.31-34 
Numerous APOBEC1 dependent C to U editing events have also been recently found in 3’-UTR of 
many mRNAs although their exact function remains to be addressed.35 
Pseudouridine (Ψ), originally designated the “fifth nucleotide,”36 is the first of the 
nucleotide modifications detected in RNA and still the most abundant of them. In human about 
100 Ψ residues have been mapped to the small and large subunits of cytoplasmic and 
mitochondrial rRNAs.37 Some pseudouridylation sites are specifically targeted (guided) by H/ACA 
box snoRNAs38 and miss-regulation of snoRNPs, targeting U to Ψ isomerization at ribosomal 
peptidyl-transferase center, alters the structure and activity of ribosomes.39 Ψ in tRNAs roles in 
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structural stabilization of helices, mediated by hydration of its major-groove imine group that 
generally makes the Ψ-containing RNAs a little stiffer.40, 41  The complementary region of U2 
snRNA, which makes a short seven base pair helix with a consensus sequence in the intron of 
precursor-mRNAs, has a conserved Ψ residue in nearly opposite of the branch site. This Ψ 
induces the branch site adenosine residue of the intron to bulge out of the duplex, placing its 
nucleophilic 2’OH in an appropriate position to start the first trans-esterification step of 
splicing.42 Although it is not clear whether mRNAs are naturally subjected to pseudouridylation, 
Karijolich and Yu showed that during mRNA translation ribosomes do not terminate the 
polymerization at Ψ-containing stop codons, producing longer poly-peptides, both in-vitro and 
in-vivo. In order to produce Ψ-containing stop codons in-vivo, they engineered specific H/ACA 
box snoRNAs to target the isomerization of the first nucleotide (U) of the stop codons into Ψ in 
mRNA sequences.43 This raises the possibility that mRNAs and other noncoding RNAs can be the 
natural targets of pseudouridylation due to the diverse pool of expressed H/ACA box snoRNAs, 
most of them uncharacterized.44 It also indicates the possible therapeutic application of custom-
designed H/ACA box snoRNAs to remove unwanted stop codons in mRNAs generated as the 
result of point mutations in some genetic disorders.45  
N1-methyladenosine (m1A) is most studied in tRNAs as it is a highly conserved 
modification at position 58 (m1A58) of almost all eukaryotic tRNAs with few exceptions.46 
Methylation of A58 provides a positive charge, which is believed to stabilize the tertiary 
structure of certain tRNAs, and enzymes involved in its synthesis are essential for organismal 
viability.47, 48 In addition, methylation at N1 position (m1A), as it affects the Watson-Crick 
interface, unlike methylation at N6 position (m6A), affects the normal base pairing capability of 
the base thus can immediately influence the folding of RNA.  This is evident in observation 
showing that N1-methylation of A9 residue (m1A9) in human mitochondrial tRNALys shifts the 
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conformational equilibrium of unmatured tRNA precursor toward the functional cloverleaf 
structure.49 This is an example of modification-assisted/-induced RNA-folding. m1A has been 
found in ribosomal RNAs and it would be interesting to see if it naturally appears in mRNAs and 
other noncoding RNAs as well. 
4-thio-uridine (s4U) has been identified in prokaryotes. NuvA and NuvC are the two 
enzymes responsible for modifying the U8 in some E. coli tRNAs into s4U.50 Although the exact 
functions of s4U are not known failure to make the s4U results in higher susceptibility of bacteria 
to UV. Interestingly the absorbance spectrum of s4U extends into the near-UV range and UV 
exposure induces the cross-linking of s4U8 to its nearby C13.  This in-vivo cross-linking somehow 
induces the accumulation of nucleotide ppGpp, which itself is a key regulator of stress response 
in bacteria.51 It is interesting to find the other possible sites of s4U in tRNAs and other ncRNAs or 
even mRNAs.  
The ribose of the immediate first two nucleotides of the capped mRNAs is often 
subjected to methylation making 2’-O-methylated modified nucleotides (Nm). This modification 
is believed to function in cellular immunity by providing a signature to distinguish self-mRNAs 
from invading non-self RNAs, recognized by specialized RNA sensors.52, 53 The C/D box snoRNAs 
guide the 2’-O-methylation of internal nucleotides in essential regions of tRNAs, rRNAs and 
snRNAs, important for their proper functions.38 Internal mRNA methylation, by a viral encoded 
2’-O methyltransferase enzyme, has also been shown to inversely correlate with RNA translation 
rate. This methyltransferase enzyme may function to methylate the viral genomic RNA as a 
protective strategy against host immune response, and/or modulate the host physiology 
through methylation of host RNAs.54 In addition, terminal 2’-O-methylation of endo-siRNAs, 
piRNAs and plant miRNAs seems to protect their 3’-end or mark them to be recognized by 
specific proteins for downstream functions.55, 56 
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The phosphate group can also be the target of enzymatic post-transcriptional 
modifications. While most RNA polymerase II (PolII) transcripts contain the famous m7G 
containing 5’-cap structure, some of the PolIII transcripts such as U6, 7SK and B2 small RNAs 
represent a special 5’-Υ-methylphosphate cap structure required for stability of these 
transcripts.57 Enzymatic methylation of α-phosphate at 5’ end of miRNAs has also been shown 
to role in regulation of miRNA processing.58  
 
Epitranscriptome dynamics 
Appearance of some modifications in RNA shows cell type-, tissue- or developmental 
stage-specific differences. One of the best examples is the C>U editing in apolipoprotein B 
mRNA exclusively in the small intestine to make a specific isoform, ApoB48, which is shorter 
than the ApoB100 produced in the liver.31, 32 Other examples are the marked differences 
between the m6A levels in mRNAs from meiotic and mitotic cells and during sporulation of 
budding yeast, or between different plant tissues.8-10  
Beside these and some other examples, however, during the lifetime of a single cell, 
many RNA modifications show appearance and disappearance cycles upon stimulation, 
providing dynamics to the cellular epitranscriptome.  For example a precise quantitation of 
modified nucleotides in tRNAs revealed that some modifications such as Cm, m5C and m22G 
show increased levels upon hydrogen peroxide exposure.59 Another study shows that oxidative 
stress-induced increase in the methylation of C34 (by Trm4) in tRNALeu(CAA) in yeast directly 
correlates with the translation level of proteins enriched in TTG codons notably the ribosomal 
protein RPL22A. This could become achieved through increased stability of the anticodon loop 
of tRNALeu(CAA) upon methylation of C34. Interestingly loss of either Trm4 or RPL22A makes the 
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cells more susceptible to hydrogen peroxide.27 A remarkable increase in the methylation level of 
C38 in tRNAAsp in yeast in response to nutrient deprivation has also been reported.  pmt1, the 
homolog of human DNMT2, is the responsible methyltransferase for methylating the C38 
position.28 For many years, pmt1 was considered an inactive methyltransferase enzyme because 
of lack of known substrates and also due to the insertion of a serine amino acid within its 
catalytic site as compared to DNMT2.60 This targeted survey, however, demonstrated that not 
only pmt1 is an active RNA cytosine methyltransferase but its activity is also under the control of 
serine/threonine kinase Sck2 arm of the yeast nutrient signaling pathways.28  
Another example of translation of signals to RNA modifications is appearance of new 
pseudouridylation sites in U2 snRNA upon external stimuli in yeast. U2 in budding yeast has only 
three Ψ residues: Ψ35, Ψ42 and Ψ44 in normal conditions; however, upon heat shock Ψ56 and 
upon nutrient deprivation Ψ56 and Ψ93 appear in the molecule. This indicates that 
pseudouridylation can be regulatory at specific locations, differentially inducible by different 
environmental stimuli.  The inducible Ψ93 has been shown to function during pre-mRNA 
splicing.61 In addition the dynamic changes of RNA modifications has been demonstrated in 
subsets of m6A marks in eukaryotic mRNAs showing increase or decrease through stimulus-
dependent regulations.14, 15  
Increase in the level of modification at a specific site in RNA can become achieved 
through expression or up-regulation of the modifier enzymes. Appearance of new sites can be 
achieved through activation of the existing enzymes, or activation, or changes in the 
combination, of RNA and/or protein components of the modifier complexes to guide for 
modifying new RNAs and/or sites.  Conversely, modifications may passively disappear upon 
depletion or inactivation of the modifier enzymes/complexes or through increased RNA 
turnover rates to make more unmodified RNAs, or the combination of both. The most intriguing 
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finding in the field of dynamic RNA modifications in the past few years, however, is the 
discovery of FTO, a demethylase enzyme that can actively remove the methyl marks from m6A 
in RNA molecules. This is analogous to active demethylation of methyl-cytosines in DNA62. FTO 
shows strong genetic association with body weight and obesity and its loss of function results in 
problems such as postnatal growth defects as well as some cardiac abnormalities and brain 
malformations, indicating its important functions63.   
 
Figure 4. 3 | The dynamic epitranscriptome. a, Translation of external and internal signals into 
RNA modifications. External regulative or stress conditions, and internal signals such as changes 
during the cell cycle events, can drive the signaling pathways resulting in induction of RNA 
nucleotide modifications. The increase (or decrease) in the level of existing modifications as well 
as appearance of new modification sites within RNA molecules has been observed. The extent of 
modification changes, as well as the underlying signaling pathways and key regulators, and most 
importantly the outcomes (functions) of such RNA modifications remain to be explored. b, 
Active erasure of nucleotide modifications. For some RNA nucleotide modifications decrease in 
the level of modifications might be due to active enzymatic reversal of the modifications. This 
has been proven by discovery m6A demthylase enzymes (FTO and AlKBH5). These enzymes can 





Despite decades of extensive research on profiling of modified nucleotides in RNA and 
their functional analysis, and enzymology of the RNA modifiers, still a comprehensive picture of 
the cellular epitranscriptome is lacking. Recently this field has attracted more attention mainly 
for two reasons: First, due to the recent technical improvements providing the possibility of 
exploring RNA modifications in more details and accuracy, and at larger scales, higher speed and 
lower prices; second, due to the discovery of a number of new small and large noncoding RNAs 
in different organisms leading to proposing and proving novel functions for RNA molecules.  
The ultimate goal of studying RNA modifications is to fully understand the contribution 
and function of each individual modification, and the interplay between different modifications. 
However, the first step is to address how these over 100 modifications are distributed in the 
sequence of coding and noncoding RNA molecules or what the entire epitranscriptome looks 
like. Here, from the technical standpoint, we discuss “epitranscriptome profiling” by providing a 
brief overview of the classical methodologies used so far, elaborating the recent advancements, 
as well as proposing potential new directions. 
 
Classical methodologies 
Different strategies have been used in the past decades to detect and locate specific 
modifications in RNA molecules (Table 4.1). In principle, a majority of these methods belong to 
one of the two major groups.  Group one encompasses those techniques that are based on the 
unique physicochemical properties of specific modifications. These include thin layer 
chromatography (TLC), gas chromatography (GC), liquid chromatography (LC), and its coupling 
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Table 4.1. Classical methodologies for RNA modification profiling 




Hydrolyzed RNAs are subjected to separation of 
nucleotides/nucleosides, based on differential 
electromobility of charged particles (due to their 
specific mass-to-charge ratio) in an electrical field, 
followed by UV detection.  
Rarely used in the past for separation and 
detection of different nucleosides and 
nucleotides derived from RNA samples.  
 
Chromatography  Hydrolyzed RNAs are subjected to separation of 
nucleotides/nucleosides, based on their differential 
solubility in different solvents resolved by their 
retention characteristics in chromatography 
approaches such as TLC, LC or GC, followed by UV 
detection.  
Widely used in the past and still in use for 
separation and detection of different 
nucleosides and nucleotides derived from 





by chromatography approaches are specifically 
subjected to ionization followed by mass analyzer 
transfer and detection by LC-MS or LC-MS/MS 
(tandem-) mass spectrometry.   
Widely used in the past and still in use for 
characterization of nucleosides and 
nucleotides as well as defining the position of 
modified nucleotides in short stretches of 
RNA oligonucleotides.  
Reverse transcription (RT)-based 
RT on intact 
RNA 
a) cDNA sequencing determines the location of 
those modified nucleotides with naturally altered 
base pairing behavior.  
a) Widely used in the past and still in use 
for determination of the RNA editing 
sites (i.e. A>I or C>U changes).  
 b) Gel electrophoresis can determine the location of 
those modifications naturally slowing down or 
stopping the RT enzyme during first strand cDNA 
synthesis producing shorter cDNA fragments 
which can be resolved on the gel. 
b) Example: Determination of the location 
of 2’-O-methylated nucleotides (Nm) in 
RNA templates using low dNTP 




a) Chemical pretreatment followed by cDNA 
sequencing can determine the location of those 
modifications differentially react with specific 
chemicals that change the sequence information 
of the RNA molecules.  
a) Example: Cytosine RNA methylation 
(m5C) profiling by RNA bisulfite 
sequencing approaches.  
 b) Chemical pretreatment can specifically target and 
change the structure of some modified 
nucleotides enabling them to slow down or stop 
the RT enzyme during first strand cDNA synthesis.  
c) Some reagents can cleavage the RNA specifically 
at special modified nucleotides. After RT reaction, 
the shorter cDNA fragments will be resolved on 
the gel.  
b) Example: Determination of 
pseudouridine sites by CMCT treatment 
of RNA which exclusively makes the 
pseudouridines bulky arresting the RT 
enzyme during  cDNA synthesis. 
c) Example: Determination of the location 
of 2’-O-methylated nucleotides (Nm) in 
RNA templates by partial alkaline 
hydrolysis resulting in cleavage of RNA 
at random locations but never at Nm 
site as 2’- O-methylation protect the 
nucleotides from nucleophilic attacks. 
Others 
Ligation-based For some modifications, if the sequence context of the 
RNA and location of the modified nucleotide is known, 
two juxtaposed DNA oligonucleotides can be designed 
to anneal to the RNA template, one sitting exactly on 
top a modified nucleotide. The differential ligation 
affinity of T4 DNA ligase to join the oligonucleotides 
annealed to unmodified or modified transcripts will 
then show the modification status of the pool of RNAs 
for that specific RNA/modification.  
Very limited application as an analytical 
method for evaluation of the level of defined 
modifications (i.e. 2’-O-methylated 
nucleotides (Nm)) at defined positions within 
the RNA templates.   
Hybridization-
based 
Those modifications resulting in differential 
hybridization affinity of modified RNAs are analyzed by 
microarray platforms harboring the complementary 
probes. 
Has been applied for detection of 
dihydrouridine, m1G, m22G, m
1A and m62A in 
RNA molecules on array platforms.  
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with mass spectrometry (LC-MS), and capillary electrophoresis (CE) to separate and identify the 
modified nucleotides based on their physicochemical properties.64 Although these techniques 
are best for characterization and quantification of modified nucleotides and have provided us 
with a massive backup of knowledge about the diversity and levels of modified nucleotides in 
RNA, except in limited cases they fail to show the exact location of the modifications within the 
RNA molecules. Members of the second group of technologies, in contrast, can show the exact 
location of the modifications as they rely on the effect of modified nucleotides on fidelity, speed 
and processivity of reverse transcriptase (RT) enzymes during first strand cDNA synthesis.65 It is 
also worth mentioning that the differential chemical reactivity of many of modified nucleotides 
has been recruited efficiently in order to expand the applications of these two methodologies 
for studying more diverse modifications and/or to increase the resolution of the techniques.66 In 
addition to the two major methodologies mentioned above a few other strategies have also 
been devised and used recently with slightly different principles. These include a microarray-
based technique, which is based on the differential hybridization affinity of modified RNA 
molecules to complementary probes on an array platform,67 and a ligation-based technique, 
which relies on the differential ligation affinity of T4 DNA ligase to join two juxtaposed DNA 
oligonucleotides annealed to an RNA template, one sitting exactly on top of a modified 
nucleotide.68, 69 These two strategies, though used successfully to detect or verify the modified 
nucleotides in real biological samples, are yet to be fully implemented for broader applications 
due to some technical limitations.  
All these technologies together have helped the scientists to discover more than 100 
distinct modified nucleotides in RNA, and determine the distribution of some of them in 
different transcripts. However, the greater extent of knowledge about tRNA and rRNA 
modifications is not comparable to what we know about modification of other RNA species, 
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while the presence of many modifications is anticipated in most RNAs. This is probably the result 
of at least three different factors.  First, the tRNAs and rRNAs are highly modified transcripts, a 
requirement for effective regulation of the fidelity and rate of translation both in normal and 
stress conditions. Especially tRNAs with their short length of about 75 bp, on average bear about 
13 modified nucleotides in each transcript. This greater level of modification has made them the 
first obvious targets of RNA modification studies. Second, tRNAs and rRNAs are the most highly 
abundant transcripts in every cell type. This higher level of transcripts has made them the first 
available targets of RNA modification studies. Conversely, the higher transcript level of the 
highly modified tRNAs and rRNAs makes it extremely difficult to purify any of the other RNA 
species without contamination with these two, even with today’s protocols. The impurities in 
the RNA preps increase the false discovery rates and decrease the resolution of the surveys. 
Finally, the detection limit of the classical epitranscriptome profiling approaches as well as their 
low-throughput format has made them most suitable for epitranscriptome profiling of the highly 
abundant and modified RNA species. Therefore, characterization of low copy modified RNA 
species and/or RNAs with low modification penetrance has been hampered by lack of powerful 
sensitive technologies. 
  
High-throughput sequencing approaches 
Concomitant with revolutionary impact of high-throughput sequencing on large-scale 
and comprehensive genome studies,70 sequencing reverse transcribed RNA molecules (cDNAs), 
using the same platforms, known as RNAseq, indeed revolutionized the area of transcriptome 
studies.71 RNA-seq is currently used for transcriptome-wide expression profiling and has clearly 
proven its superiority over microarray-based techniques. The still increasing power and 
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decreasing cost of the technique in conjunction with the possibility of barcoding, which allows 
sequencing of several samples in a single lane, has made this technique the method of choice 
for almost all transcriptome-wide studies. This technology has recently been used for 
epitranscriptome profiling of few modified residues, notably m5C, m6A and I revealing some new 
biological insights for them. In principle the high-throughput sequencing approaches we discuss 
here are the extension of classical RT-based approaches with much higher sensitivity, and 
sometimes with some changes enabling their application as more of discovery rather than 
analytical techniques.  Detection of many modifications using such approaches does not require 
much prior knowledge about the extent and distribution of the modified nucleotides within the 
transcripts. Here, we introduce different strategies for epitranscriptome profiling using the high-
throughput sequencing approaches (see Figure 4.4).   
 
Direct detection by high-throughput sequencing 
A majority of modified nucleotides behave the same as standard nucleotides during 
reverse transcription and cDNA synthesis and are therefore called “RT-silent.” However, some 
modifications change the standard A:T, C:G base pairing rules and some others may decrease 
the RT rates or even completely block the progression of cDNA synthesis. Such modifications can 
introduce single nucleotide variations (SNVs) or produce truncated cDNAs indicating the sites of 
the modified nucleotides upon analyzing the sequencing reads at base pair resolution. Detection 
of the frequent sites of modifications regardless of the modification type could be possible 
through analyzing the available RNA-Seq datasets generated for other purposes. In addition RNA 
samples can be sequenced and analyzed, considering proper controls, with the intention of 





Figure 4.4 | High-throughput epitranscriptome profiling approaches. See text for details.  
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Over the past few years massive RNA-Seq datasets covering the entire transcriptome of 
many organisms have become publically available. Limited bioinformatics analysis of such 
datasets has been specifically used to find the locations of frequent sequencing errors as 
possible sites of modified nucleotides. These works revealed a number of known and new 
modification sites within small RNAs such as tRNAs and miRNAs, demonstrating that not all of 
the so called “sequencing errors” are true artifacts but rather a subset of them could be simply 
real sites of post-transcriptional RNA modifications.72, 73 This may explain, to some extent, the 
controversies over a work reporting widespread differences between the sequences of RNA and 
DNA in the human transcriptome. The report claimed the identification of more than 10,000 
sites in human mRNAs.74 Several groups later on commented on the work and suggested that 
majority of these sites are most likely artifacts due to misinterpretation as the result of analysis 
errors such as neglecting the genetic variations as well as sequencing or mapping errors.75-77 
However, neither of the report itself nor the comments specifically considered the post-
transcriptional nucleotide modification as one potential cause of at least a subset of those 
RNA/DNA differences, while this is practically anticipated. Overall, bioinformatics analysis of the 
available datasets can help to identify the frequent and reproducible sites of RNA/DNA 
discrepancies as the candidate sites of RNA modifications become experimentally verified.    
For a few defined RNA modifications, capable of changing the standard base pairing 
rules, comparison of transcriptome with the source genome has been efficiently used to readily 
identify the sites of modifications. The A>I and C>U editing are the well established examples of 
the application of this approach and there are a number of reports for detection of such editing 
sites using both classical approaches in the past and high-throughput sequencing approaches in 
recent years. To accurately identify the sites of such modifications RNA extracted from the cells 
lacking the responsible enzyme could be used as a definitive control. It would be interesting to 
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experimentally survey the base pairing behavior of all other modified nucleotides to find those 
that can become simply identified by row sequencing of the RNA. For example, s4U shows a 
greater tendency to base pair with G than A inducing some levels of U>C transition upon 
reverse-transcription and sequencing, thus potentially becoming readily identified, although it 
has not been explored this way yet.78 In addition, for those modifications that cause the delay or 
pause during reverse transcription, mapping might be possible through data analysis by looking 
for the sites of cDNA truncation.    
Overall, direct detection of the sites of modifications within RNA transcripts via analysis 
of the high-throughput sequencing datasets is a quick way of epitranscriptome profiling for 
limited types of modifications. However, this approach, like other approaches discussed in this 
report, is prone to both false positives and negatives. The false positives may come from 
sequencing and mapping errors or genetic variations. The false negatives may be due to multiple 
sources such as the higher turn-over rates of modified RNAs, the transcripts’ low copy number, 
the low penetration of modification at a given site, the incomplete effect of some modifications 
on the base change or RT arrest, the dynamic changes of modifications (erasure and writing 
cycles), possible transcript destabilizing modifications, and placement of the RT pausing or 
blocking modifications at the very 3’ end of the transcript preventing the primer extension and 
detection of the modified RNA. All these possibilities should be considered in any discovery or 
analytical approaches to avoid errors in mapping of the modified nucleotides.   
 
Pretreatment coupled with high-throughput sequencing 
Pretreatment of RNA with chemical or enzymatic mixtures prior to cDNA synthesis 
followed by sequencing can expand the applications of RNA-Seq for modification detection.65, 66 
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The principle is the differential reactivity of the specific modification under study with a 
chemical compound or in a special enzymatic reaction. The goal could be either of (1) changing 
the base pairing properties of the nucleotides, (2) cleaving the RNA at or next to the modified 
nucleotides, or (3) converting the modified nucleotides into bulky structures to block the RT 
enzymes during cDNA synthesis. Single nucleotide variations can be deduced directly by 
inspecting the mapped sequencing reads at base pair resolution, and sites of cleavage or RT 
arrest can be found by observation of frequent split or truncation of the reads. For either of 
these experiments RNA samples extracted from knock-down or –out cells lacking the 
corresponding RNA modifier could be used in parallel to filter for the possible false positives.  
Detection of m5C in RNA by bisulfite sequencing is the most well known example of 
pretreatment coupled with sequencing which has been applied in both of small and large (high-
throughput) scales.17, 79 In this procedure all the Cs but not m5Cs in RNA get converted to Us 
which after sequencing shows the sites of Cs as  Ts and sites of m5Cs as maintained Cs.  
Recently chemical oxidation of 5-hydroxymethylcytosine (hm5C) to 5-formylcytosine 
(f5C) prior to bisulfite sequencing has been applied to identify the locations of hm5C sites in DNA. 
f5C unlike m5C and hm5C undergoes deamination and therefore gets converted to U (T after 
sequencing) marking the precise location of hm5C in the genome.80 In another report enzymatic 
oxidation of hm5C to 5-carboxylcytosine (ca5C) by TET proteins was used for a similar purpose as 
again bisulfite treatment efficiently deaminates the ca5Cs.81 As hm5C has been detected in RNA 
similar strategies can be used to differentiate it from m5C and find the exact locations of 
hydroxymethylated cytosines in bisulfite treated RNA.82   
The other example of similar strategies is the direct detection of A>I editing sites by 
cyanoethylation of inosine. While knockdown of adenosine deaminase enzymes as the standard 
control for detection of true editing sites can introduce some unwanted transcriptome-wide 
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changes, cyanoethylation of inosine on the wild-type RNA samples can show the editing sites by 
blocking the primer extension over the cyanoethylated inosines resulting in loss of edited RNAs 
during library preparation and manifested by lack of A>G changes in those sites exclusively in 
the treated but not untreated samples.83 
Some reagents are known to selectively depurinate specific modified nucleotides.64 If 
the integrity of RNA remains intact during the procedure the depurinated sites can become 
possibly identified by cDNA sequencing indicating the sites of sequencing errors (modifications 
sites). 
Detection of specific modifications through induction of selective RNA cleavage or RT 
arrest, upon special chemical pretreatment, has been used for detection of m7G or Ψ, 
respectively, by small scale Sanger sequencing. The RNA cleavage produces shorter fragments 
that can be used separately for library preparation, and the RT arrest produces truncated 
cDNAs.65, 66 Thus, the outputs of both of these procedures can be directly sequenced along with 
proper controls using high-throughput sequencing approaches to find the locations of RNA 
cleavage or RT arrest as the possible sites of RNA modifications.   
Overall, a comprehensive thorough survey seems to be required to explore the 
differential reactivity of all modified nucleotides, with different chemical reagents or within 
specific enzymatic reactions, in order to develop specific pretreatment procedures facilitating 
the detection and mapping of modified nucleotides within the RNA molecules.  
 
Enrichment coupled with high-throughput sequencing 
Beside the highly abundant tRNAs and rRNAs, other ncRNA species and mRNAs are 
expressed at moderate to very low levels. Some RNA species are so scarce that their abundance 
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is considered generally less than one transcript per cell, meaning that in several cells only one 
copy may be found44. In addition the penetrance of modification at a particular site as well as 
the turnover rate or dynamic manifestation of a given modification, as the result of cyclic 
writing/erasing processes, can bring the level of modified RNA species below the detectable 
threshold. Finally the combination of these two scarcities (low-copy RNAs and low-penetration 
modifications) will make it even worse to capture and study such modified RNAs. The less 
abundant RNA species including the very rare ones can be considered equally, if not more, 
interesting in comparison to their abundant tRNA and rRNA counterparts. Also the low-level 
modification events may contribute in marking a subset of transcripts for specialized functions 
and thus it could be interesting to isolate and characterize them. All these indicate the 
importance of development and application of enrichment techniques for detection of rare 
modification events. Enrichment can be achieved through depletion of the abundant tRNAs and 
rRNAs from the total RNAs. However, even with current depletion protocols a clean RNA 
preparation is hard to obtain. Alternatively the modified RNAs themselves can be the subjects of 
enrichment. Here we introduce, and give examples for, different applied or novel strategies of 
enriching the modified RNAs, including techniques based on (A) differential chemical reactivity 
of modified RNAs, (B) affinity of antibodies or specific binding proteins for modifications, or (C) 
reaction mechanisms of the corresponding RNA modifier enzymes.  
 
Differential chemical reactivity-based enrichment  
Each modified nucleotide is a distinct structure with specific chemical properties. Thus it 
may be possible to use special reagents to specifically enrich the modified RNAs. piRNAs and 
miRNAs in some species contain 3’ terminal 2’-O-methylated nucleotides. Taking advantage of 
94 
 
the methyl group at the 2’ position of the terminal sugar, to enrich for the methylated piRNAs, 
researchers have developed a smart protocol to make cDNA selectively from the methylated 
RNAs. In this protocol treatment of small RNAs with NaIO4 followed by β-elimination results in 
the removal of the 3’ terminal nucleoside leaving a 3’ phosphate. The terminally 2’-O-
methylated nucleotides are refractory to this reaction and remain intact. During library 
preparation for sequencing, the 3’ phosphate at the end of small RNAs blocks the 3’ adapter 
ligation resulting in the loss of corresponding cDNAs in the library and enrichment of cDNAs 
made exclusively from the methylated RNAs.84 With a similar concept the m7G capped RNAs can 
be enriched by treating the total RNA with calf intestinal alkaline phosphatase (CIP) to remove 
the phosphate group from all un-capped RNAs and leave a 5’-OH followed by tobacco acid 
pyrophosphatase (TAP) treatment to break the cap structure and leave the capped RNAs with a 
clonable 5’ monophosphate. The 5’ adapter can then be ligated exclusively to the 5’ 
monophosphate RNAs to reveal the profile of capped RNAs in the cells.5  
Differential chemical reactivity has also been used for enrichment of DNA fragments 
harboring hm5C through enzymatic glycosylation of hm5Cs followed by biotinylation, capture by 
streptavidin beads, release and then sequencing. The exact same protocol might be useful to 
detect hm5Cs in RNAs, and similar strategies can be developed to capture the RNA molecules 
containing other modified nucleotides.85  
 
Affinity-based enrichment  
Most modified nucleotides are distinct enough and immunogenic to raise specific 
antibodies against them and some may have natural protein binders recognizing them in the 
cells. Anti-m6A antibody has recently been used to explore the transcriptome wide distribution 
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of this modification in RNAs.14, 15 Anti-m7G cap structure antibodies have also been used for 
enrichment of capped RNAs.5 Alternatively, the cap binding protein eIF4E can be used to 
specifically enrich the m7G capped RNAs.86   
Additionally RNA targets of modifier enzymes can be captured through UV or chemical 
reagent enhanced cross-linking of the enzymes to their RNA substrates followed by enrichment 
of the complex via enzyme specific antibodies. The reverse cross-linked RNAs can then become 
recovered for cDNA library preparation and high-throughput sequencing to identify the target 
RNAs. Development of antibodies against the modifications or the modifier enzymes or 
discovery and application of natural protein binders seems to be a more available strategy for a 
majority of RNA modifications/modifiers.    
 
Mechanism-based enrichment 
As explained above capturing the substrates of RNA modifying enzymes is one way of 
studying the modified RNAs, which can be achieved through cross-linking of the target RNAs to 
the enzymes via UV irradiation or use of different chemical cross-linkers. This approach is an 
“interaction-based” enrichment strategy that may suffer from both false positives and 
negatives. A given modifier enzyme in order to reach its target molecule may encounter some 
nontarget RNAs and once finding the right target may inspect many nucleotides to find and 
modify the exact target nucleotide. An affinity-based technique potentially not only enriches the 
true substrates but may also enrich some of the nonsubstrate interacting bound RNAs. On the 
other hand the on/off rate of most enzymatic reactions is very fast decreasing the chance of 
capturing the true RNA substrate-enzyme complexes, which can be the source of false 
negatives. It is therefore useful to apply “reaction (mechanism)-based” enrichment approaches 
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to capture the RNA substrate-enzyme complexes only when the real modification reaction is 
involved. This could potentially generate higher resolution and cleaner background.  
Recently we have reported a mechanism-based enrichment method called Aza-IP to 
capture the direct in-vivo targets of RNA cytosine methyltransferases (m5C-RMTs).87 Aza-IP takes 
the advantage of the reaction mechanism of cytosine methyltransferases involving a covalent 
connection during the methylation process. Random transcription-dependent incorporation of 
nucleotide analogues such as 5-aza-cytidine (5-aza-C) at the exact target site of the m5C-RMTs 
within a given target RNA stops the methylation cycle in the middle and results in formation of a 
stable RNA-RMT adduct intermediate, connected through the covalent linkage between the 
active site of the enzyme and 5-aza-C. This RNA-RMT adduct can be enriched via application of 
specific antibodies against the enzyme. The covalent linkage is stable enough for efficient 
immunoprecipitation, but is also reversible by application of heat and/or chemical reagents to 
release the RNA for cDNA synthesis and sequencing. Surprisingly, the release step induced a C>G 
transversion signature at the exact target sites of known m5C-RMT target sites within the RNA 
molecules enabling the direct detection of the precise target sites within the target RNA 
substrates. This approach helped to identify all known tRNA targets of human DNMT2 and 
NSUN2 and also revealed many novel NSUN2 target sites within tRNAs and several ncRNAs. 
Similar strategies under a general term of “Adduct-IP” have also been suggested for 
identification of the direct targets of some other RNA modifiers.87 In principle if a covalent 
linkage is involved in a given modification reaction and upon availability of appropriate 
nucleotide analogues Adduct-IP can be applied to find the targets. We propose the application 
of Adduct-IP for target identification of at least some other RNA modifiers such as 
pseudouridine synthases and uracil methyltransferases. The 5-flurouracil has been shown to 
block these enzymes and produce RNA-enzyme adducts through a covalent connection.88  
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Adduct-IP may also be done without using the nucleotide analogues in special cases. For 
example the NSUN family of methyltransferases utilizes two cysteine residues for the catalysis, 
one for forming the covalent connection with the target cytosine base and the other for 
releasing the RNA after the completion of methylation.16, 89 Experiments have shown that 
mutation of the second cysteine to another amino acid will interfere with the release step and 
results in the formation of an RNA-RMT adduct.90, 91 This RNA-RMT adduct can become 
efficiently enriched via immunoprecipitation and the RNA can then be released and sequenced. 
Interestingly, because the target cytosines of the released RNAs are methylated, bisulfite 
sequencing of the enriched RNAs might be helpful for identification of the RMT target sites. 
Alternatively, the target site can be defined by degrading the RMT enzyme of the adduct by 
proteinase K treatment leaving few amino acids attached to the RNA at the exact target site. 
Upon cDNA synthesis the protein left-over will block the RT enzyme revealing the exact target 
sites.91  Overall such release mutant RNA modifiers can be over-expressed in the cells for 
isolation of the direct targets of some modifier enzymes. Even for those modifier enzymes in 
which the covalent intermediate is not involved or the release mutant cannot be efficiently 
made any mutation that decreases the off rate, but does not affect the target specificity of the 
enzyme, can help to establish the Adduct-IP procedure. In such cases chemical cross-linking can 
also come into play to boost the stability of the RNA-RMT adduct during immunoprecipitation. 
Overall, it would be interesting to explore the catalytic mechanism of all RNA modifier enzymes 
in order to construct suicide nucleotide analogue inhibitors, or to find the appropriate 
mutations that may decrease the off rate of the enzymes suitable for application of the Adduct-
IP type of approaches for their target profiling. 
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Modification detection by advanced sequencing technologies 
Current high-throughput sequencing approaches rely on utilizing the DNA/cDNA 
libraries made from small (fragmented) pieces of nucleic acid polymers, which have been copied 
many times from the original templates. The smaller sizes often cause problems in accurate 
mapping of the sequenced reads, and amplification cycles quite often introduce biases and also 
unwanted single nucleotide errors. Especially, for the case of modification profiling in both the 
DNA and RNA current approaches and strategies allow detection of only a single type of 
modification at a time, and when looking for multiple modifications in the same molecules 
multiple sequencing experiments should be performed. Finally there are still no reliable 
approaches or tricks for differentiation and detection of many modifications with current 
sequencing technologies.  
To circumvent the current size limit of the sequencable molecules and to bypass the 
amplification cycles during library preparations, new single molecule sequencing technologies 
are emerging (Figure 4.5). Notably, these technologies can readily differentiate the modified 
from standard nucleotides, and in principle are able to detect multiple modifications at a time, 
in both DNA and RNA.2 In addition, by such technologies, prior cDNA synthesis is no longer 
required as RNA can become directly sequenced. Here we introduce three different platforms; 
each utilizes a substantially unique principle for single-molecule real-time sequencing. Although 
these technologies have not yet been fully implemented for RNA sequencing some successful 
reports of RNA sequencing as well as efficient nucleotide modification profiling in DNA indicate 
their potentials to be applied more widely for both RNA sequencing and modification profiling. 







Figure 4.5 | Advanced single-molecule RNA sequencing approaches. a, Single-molecule, real-
time (SMRT®) RNA sequencing. Schematic shows a reverse transcriptase enzyme fixed on a 
surface at the bottom of a nanochamber. The RNA molecule (red) is used as the template for 
real-time sequencing through cDNA synthesis. Special phospholinked fluorescent standard 
nucleotides (A, C, G and T), labeled with different fluorescent molecules at their terminal 
phosphates, are present in the mixture. The cDNA synthesis is catalyzed continuously without 
interruption. Each time a nucleotide is added to the growing cDNA chain a distinct fluorescent 
pulse is generated and recorded.  The pulse width (PW; the nucleotide retention time in the 
polymerase active site) and the interpulse duration (IPD; the time interval between the 
nucleotide-bond states) generated as the result of addition of the complementary nucleotide in 
front of the modified nucleotide (within the RNA) will be distinct enough to make a unique 
signature for detection of individual modifications. b, Nanopore RNA sequencing. The RNA 
molecule can become driven through a nanopore allowing the passage of individual nucleotides 
through the channel one-by-one. Each individual nucleotide (standard or modified) will 
specifically change the flow of ions in the channel resulting in generation of a unique change in 
the electrical current to be used as a unique identifier of that standard or modified nucleotide. c, 
Microscopy-based RNA sequencing. RNA molecules can become deposited individually on 
special surfaces, like single-layer graphene, for taking their image by transmission electron 
microscopy (TEM) or scanning tunneling microscopy (STM). The image processing can reveal the 
sequence of the RNA molecules and possibly find the location and nature of the modified 
nucleotides. A schematic example using the STM technology is given here.  
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 1. Single-molecule, real-time (SMRT®) DNA sequencing uses a DNA polymerase fixed at 
a bottom of a nano-chamber, and a single stranded DNA template for real-time DNA 
polymerization and sequencing.  In this procedure special phospholinked fluorescent standard 
nucleotides, labeled with different fluorescent molecules at their terminal phosphates, are 
sequentially added to the growing DNA strand without interruption for washing. Upon addition 
of each nucleotide, a specific fluorescent pulse is generated and recorded showing the type of 
the added nucleotide. During this continuous polymerization, when facing a modification in the 
template, the pulse width (PW; the nucleotide retention time in the polymerase active site) and 
the interpulse duration (IPD; the time interval between the nucleotide-bond states) will be 
distinct enough to make a unique signature for each individual modification.92 SMRT® DNA 
sequencing has been successfully applied for simultaneous detection of multiple natural DNA 
modifications such as m5C, hm5C, m6A and m4C as well as characterization of many DNA damage 
induced modifications such as 8-oxo-G, 8-oxo-A, O6-methyl-G, etc.2, 93-96  It has also recently 
been applied for direct m6A profiling in RNA through replacement of the DNA polymerase with 
reverse transcriptase in the platform.97  
2. Nanopore single-molecule DNA sequencing is another promising sequencing 
approach potentially capable of detecting modifications in DNA and RNA.2 In contrast to all 
previously applied sequencing approaches this approach does not require any polymerization 
reactions. Instead the nucleotides of a single-stranded DNA molecule are driven through a 
nanoscale pore one-by-one and the changes in the electrical current, caused by passage of 
individual nucleotides and alteration of ion current within the channel, are recorded to 
determine the nucleotide type.98 Theoretically any distinct nucleotide structure including the 
modified ones should produce a unique signal enabling their detection, and in practice 
nanopore sequencing has been successfully applied for m5C and hm5C profiling in DNA.99, 100 
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Development of nanopore technology for direct protein sequencing101 as well as for direct RNA 
sequencing and RNA modification mapping102 is under progress.  
3. Microscopy-based imaging has also been added to the list of single-molecule DNA 
sequencing technologies.2 In this approach pictures obtained by transmission electron 
microscopy (TEM) or scanning tunneling microscopy (STM) from ordered arrays of DNA 
molecules, deposited individually on special surfaces like single-layer graphene, are analyzed to 
detect the order of nucleotides in each DNA molecule.2, 103, 104 Although this strategy still 
requires full implementation it has been applied, with some modifications, for detection of m5C 
in DNA.105 RNA sequencing and RNA modification profiling with this technology might become 
available in future.    
  
Outlook 
Post-transcriptional RNA modifications, in parallel with postreplicational DNA and post-
translational protein modifications provide extra layers of information complexity for the flow of 
genetic information and are fundamental for survival, adaptation and evolution of living 
organisms from all three kingdoms of life.  
All modified nucleotides, mentioned in this review, along with tens of others that are 
not discussed, shape the complex RNA “epitranscriptome” of the cells. Many of these 
modifications are essential for life and loss or gain of function of the responsible modifier 
enzymes or their accessory components can result in cancer, infertility, metabolic and immune 
diseases, as well as genetic disorders such as neurological or cognition abnormalities. 
Understanding the distribution and function of individual modified nucleotides, and their 
possible interplay and interactions with each other, as well as characterization of the modifier 
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enzymes and complexes, will provide a valuable level of knowledge for better understanding of 
life. Elucidating the epitranscriptome differences in different cell types or tissues as well as 
changes during development and upon stimulation or during stress conditions or immune 
response can also provide additional layers of knowledge about the impact of dynamic RNA 
modifications for the cells. 
For several decades, due to technical limitations our knowledge about the scope and 
functions of RNA modifications was restricted to the highly abundant and highly modified tRNAs 
and rRNAs. Pretty recently, however, results obtained by application of high-throughput 
sequencing technologies along with discovery of diverse families of novel ncRNAs attracted 
more attentions to the field, with the aim of discovering possible nucleotide modifications 
affecting the structure or function of all or a subset of transcripts. Targeted projects by several 
research groups revealed many new sites of modifications of different types in both of coding 
and non-coding RNAs proving that RNA modifications are more widespread than it was initially 
thought to be. Currently the epitranscriptome field is open for both of evidence or hypothesis 
driven, and small- or large-scale (transcriptome-wide) studies to explore new biological 
territories and answer to a number of long lasting questions in the field, and several live projects 
are currently going on in different laboratories worldwide.  
To enhance the growth of knowledge in the field, systematic comparison of massive 
available row RNA sequencing datasets deposited in public databases with the intention of 
finding the sites of frequent, consistent and/or conserved DNA/RNA discrepancies can help to 
prepare a list of candidate modified sites within the transcriptome for further verifications. 
Examining the base pairing behavior of all known modified nucleotides will help to design 
experiments for their direct mapping within the RNA by parallel sequencing of the RNA samples 
extracted from wild-type or RNA modifier null cells/organisms.  
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It is also interesting to expand our knowledge about the differential reactivity of all 
modified nucleotides, with different chemical reagents or within specific enzymatic reactions for 
developing specific pretreatment procedures facilitating their detection/enrichment and 
mapping.  
Development and use of antibodies against either of modifications, themselves, or their 
corresponding modifier enzymes can help for enrichment and more focused analysis of the 
modified RNAs. Similarly isolation and characterization of possible proteins capable of binding 
specifically to the modified nucleotides would be helpful. Elucidation of reaction mechanisms of 
different RNA modifiers at molecular level can help to establish reaction-based enrichment 
methods for more reliable detection and mapping of the direct substrate RNAs. Finally, 
application of the emerging real-time single-molecule sequencing technologies can help to 
increase the spectrum as well as resolution of the epitranscriptome mapping.  
Altogether, it is anticipated that in the near future, these diverse types of classical, 
current and future technologies will help improve our understanding of the cellular 
epitranscriptome, its logic, dynamics, diverse functions, and overall impact on living organisms. 
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In the introductory chapter of this dissertation (Chapter 1), we briefly discussed the 
emerging field of RNA epitranscriptome, with more emphasis on m5C modification and m5C-RMT 
modifier enzymes. As previewed, in spite of their biological importance, little is known about the 
scope, targets and processes involving many RNA modifying enzymes, including RNA cytosine 
methyltransferases, largely due to the absence of techniques to precisely map the modifications 
within RNA molecules and/or accurately link the modifier enzymes to their precise substrates. 
This indicates the importance of employing the existing, and developing novel innovative 
techniques to discover the RNA epitranscriptome as a whole, with high resolution and accuracy. 
In the second chapter we introduced an improved version of the existing RNA bisulfite 
sequencing techniques and presented a comprehensive high-resolution RNA cytosine 
methylome of mouse embryonic fibroblasts (MEFs) in wild type and Dnmt2 null mice. In that 
chapter we also discussed caveats of RNA bisulfite sequencing techniques and their possible 
false positives and negatives to be considered in experimental designs and data interpretation 
steps, indicating the need for development of complementary robust techniques to increase 
both the resolution and accuracy of the m5C site calls.   
In keeping, in the third chapter, we introduced a substantially innovative technique; 
Aza-IP, for identification of the direct targets and modified bases of m5C-RMTs in a single 
experiment and with high accuracy.1 We presented the obtained results with the Aza-IP 
technique for m5C-RMTs from two different families, representing both ‘single cysteine’ 
(DNMT2) and ‘two-cysteine’ (NSUN2) type enzymes. Aza-IP revealed all of the known target 
tRNAs and precise target sites of DNMT2 and NSUN2, as well as hundreds of novel and 
previously unappreciated NSUN2 target sites within those tRNAs. We also reported several 
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known and novel ncRNA targets of NSUN2 with the precise targets, validated, for selected target 
sites, with conventional RNA bisulfite sequencing.  
In Chapter 4, we presented an overview of all classical, recently developed, and 
currently available techniques, as well as potential technical strategies to be applied in future 
for RNA epitranscriptome profiling. In that overview we discussed how strategies similar to both 
of RNA bisulfite sequencing and Aza-IP can become adapted to explore the distribution and 
functions of other modifications beside m5C in diverse RNA species.  
Here in this chapter we present the future directions of this work to address 
fundamental questions of the field regarding m5C and m5C-RMTs. 
 
Future directions 
Isolating the direct RNA substrates of all human m5C-RMTs 
About ten different human m5C-RNA methyltransferases (m5C-RMTs) have been 
identified so far; NSUN1, 2, 3, 4, 5 (A, B & C), 6 and 7, and DNMT2.2 Beside NSUN2 and DNMT2 
all the other human m5C-RMTs are remained largely uncharacterized. Here we aim to provide a 
comprehensive catalogue of the target RNA molecules and the target cytosine bases of all 
human m5C-RMTs in HeLa cells, and also provide tissue-specific information about the target 
profiles of the human m5C-RMT homologues in mice and/or zebrafish. This will provide a critical 
foundation for the entire field for future studies on this important class of enzymes. Based on 
these results we also aim to propose and test some candidate functional targets for m5C-RMTs 





Target profiling of all other human m5C-RMTs by Aza-IP  
Our success with the Aza-IP technique using m5C-RMTs from two different families, 
representing both ‘single cysteine’ (DNMT2) and ‘two-cysteine’ (NSUN2) type enzymes, strongly 
suggests that Aza-IP may serve as a general technique for enrichment of direct targets of any 
cytosine methyltransferase that utilizes a similar catalytic mechanism. Here we will apply Aza-IP 
for target profiling of other human m5C-RMTs.  We will explore the known and candidate NSUN 
family methyltransferases NSUN1, 3, 4, 5(A,B,C), 6 and 7. Similar to our previous procedure with 
DNMT2 and NSUN2, V5-tagged full-length enzymes will be expressed in HeLa cells using 
lentiviral expression systems, with application of the same 5-aza-C concentration and exposure 
time.  As before, we will perform two biological replicates and an IgG control. The USeq3 and 
VarScan4 packages will then be used to find the enriched RNAs and the exact target cytosines, 
respectively. This work will provide a comprehensive catalogue of the target sites of m5C-RMTs 
in HeLa cells.  
 
Adduct-IP for tissue-specific RNA methylation analysis 
A clear and important issue in RNA methylation analysis is to determine the repertoire 
of targets for m5C-RMTs in different cell types and contexts.  In principle, Aza-IP should be 
extendable to models systems, such as the mouse, which harbors orthologs of all human m5C-
RMTs.  Here, one could administer 5-aza-C to mice, perform Aza-IP with a polyclonal antibody 
created/verified for IP, and follow the prior regimen to reveal targets.  Here, pilot experiments 
would be performed involving various doses of 5-aza-C, dissection of various tissues of interest, 
the use of mass spectrometry to quantify the 5-aza-C:cytosine ratio in those tissues, and pilot 
Aza-IP experiments performed in a multiplexing format. It seems reasonable to initially pilot the 
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technique with DNMT2 or NSUN2 (as targets are already known) to test and calibrate the 
system before moving on to m5C-RMTs with unknown targets. We consider this approach 
reasonable and feasible and likely to work given sufficient effort.  However we have elected to 
consider this line of experimentation as an ‘alternative approach’ rather than the main approach 
to determine tissue-specific targets, and provide two reasons. The first involves a slight concern 
regarding the likely extent of 5-aza-C incorporation into RNA in a mouse model. During 
transcription 5-aza-C is randomly (and nonpreferentially) incorporated in place of cytosine. 
Notably, our Aza-IP regimen involves the growth of HeLa cells in media with relatively low levels 
of 5-aza-C (3-5μM to avoid toxicity).  Although the precise 5-aza-C:cytosine ratio in HeLa RNAs 
isolated from this regimen has not been determined, it is almost certainly very low, and this 
ratio sets an upper limit on the proportion of target RNAs that can be covalently linked to the 
tested m5C-RMT.  This is coupled to concerns about bioavailability and stability of the compound 
in certain tissues. Together, although these issues are surmountable, optimization will likely 
require a lengthy pilot phase and large numbers of mice to provide sufficient material. The 
second reason for relegating Aza-IP to an ‘alternative approach’ is an interest in pursuing an 
alternative (below). 
To circumvent these limitations we propose to take advantage of an intrinsic feature of 
the catalysis mechanism of ‘two-cysteine’ m5C-RMTs to test another novel technique: Adduct-IP. 
Nine out of the ten known human m5C-RMT are from the NSUN methyltransferase family, which 
utilize two cysteines in their catalytic domains. As explained in previous chapters, to conduct 
methylation, a particular cysteine (from motif VI), attacks the base and forms the covalent RMT-
RNA intermediate, driving the methylation of the C5 position of cytosine. For completion of the 
methylation cycle and enzyme release, the other cysteine (from motif IV) triggers the reversal of 
the covalent connection and release of the base from the enzyme.2, 5 Published work (both in-
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vitro and in-vivo) has shown that mutation of the motif IV cysteine will result in formation of 
stable covalently connected RMT-RNA adducts.6, 7 Here we aim to take the advantage of this 
characteristic feature in developing the novel “Adduct-IP” technique for isolation of the direct 
targets of m5C-RMTs in tissues of model organisms (Figure 5.1).  
 
Adduct-IP in mice 
To perform Adduct-IP, we will generate transgenic mice expressing an epitope-tagged 
version of cysteine-mutant m5C-RMTs under the control of Tet-On system.8 Rapid expression of 
the mutant enzymes will be triggered by doxycycline treatment, and the animals will be 
sacrificed at the proper time (determined by pilot experiments involving NSUN2, see below, but 
likely after 1-3 days). We will pilot Adduct-IP with NSUN2, as it has been studied extensively in 
mammals, with gain of function linked to cancer,9-11 and loss of function linked to infertility,12 
intellectual disability and mental retardation.13-15  Given these links, it seems obvious to include 
the brain and testes in the initial panel of tissues, and if interesting new RNAs emerge, it can 
motivate the sorting of cells from these tissues to find cell-type specific RNA targets.  The 
dissected tissues will be subjected to IP with proper replicates and controls (again, calibrated 
initially by NSUN2). The RNA will be released from the enzyme using the fragmentation protocol 
(as with Aza-IP) and the RNA will be subjected to sequencing. Here, we expect to capture 
virtually all of the tissue-specific direct targets of specific m5C-RMTs. However, because we do 
not use 5-aza-C, further analysis and experiments are required to determine the exact target 
cytosines within the enriched RNAs (beginning with focused/directed RNA bisulfite sequencing 
on enriched targets, likely in a multiplexed MiSeq format). We anticipate Adduct-IP to provide 








Figure 5.1 | Principle of the proposed Adduct-IP technique. a, Protein alignment of the motifs 
IV and VI of the human NSUN family (NSUN1-7) shows the conservation of the cysteine residues 
for catalysis (from motif VI), and release of the enzyme from the base after completion of the 
methylation (from motif IV). b, Adduct-IP experimental design, enabling the regulated 
expression of the release mutant  enzyme (m5C-RMT(mt)) under the control of the Tet-ON 




Beyond NSUN2, prioritization of additional m5C-RMTs and the target tissues chosen for 
testing by Adduct-IP will be determined by two main criteria: phenotypic information and 
expression patterns. Phenotypic information will involve gain or loss of function phenotypes 
both from published work and from results of this project, and the tissue-specific expression of 
m5C-RMTs will be determined by qRT-PCR and/or western blot analysis. In addition we 
anticipate that the GO (Gene Ontology) term analysis of the target RNAs isolated by Aza-IP in 
HeLa cells, may provide preliminary information about the underlying pathways, functions and 
cellular components, helpful in rational selection of target tissues for Adduct-IP experiments. 
Furthermore, as previewed above, if interesting new RNAs emerge from a tissue, it will motivate 
the sorting of cells from that tissue to possibly reveal cell-type specific RNA targets, which can 
motivate focused functional experiments.  
 
Adduct-IP in zebrafish 
An additional area of interest is RNA cytosine methylation in early embryogenesis and 
organ development. However, obtaining sufficient cell and tissue types from the mouse will 
likely be quite difficult.  However, we consider zebrafish an excellent alternative.  First, zebrafish 
harbor all of the NSUN family members (except NSUN7) present in mammals.  Second, 
thousands of embryos can be obtained and easily manipulated (injected) in a few hours 
providing enough material for the downstream experiments. Also zebrafish embryonic and 
developmental cycles are rapid, with organ development occurring within 72 hours. 
Importantly, the University of Utah and the Huntsman Cancer Institute are leaders in modeling 
diseases such as cancer in the zebrafish, and have more than twenty independent laboratories 
conducting experiments in the zebrafish.  The institution has made a major investment in 
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zebrafish facilities, which can provide the equipment and expertise that will allow us to quickly 
and efficiently adapt the Adduct-IP technique for capturing the possible targets of m5C-RMT 
homologues in zebrafish. To quickly accomplish this, in-vitro transcribed mRNAs encoding a V5-
tagged version of mutant m5C-RMTs will be injected into fish embryos and the Adduct-IP 
protocol will be applied at the desired developmental stage. Again, prioritization of enzymes, 
tissues and developmental stages will be made based on the insights provided by the results 
from previous steps. If we obtain interesting results using the injection approach, we can easily 
make transgenic fish using tissue- or cell-type specific promoters that will allow a more 
sophisticated application of Adduct-IP. 
 
Studying the roles of cytosine methylation in mRNAs and ncRNAs. 
The ultimate goal of this project is to provide insights about the possible functional roles 
of RNA cytosine methylation in living organisms. In the first phase we intend to generate a 
comprehensive catalogue of the direct targets of all human m5C-RMTs in HeLa cells, 
supplemented with tissue-, cell- and/or developmental stage-specific information about a 
prioritized subset of human m5C-RMTs homologues in mice and fish. This will provide a 
foundation for proposing and evaluating evidence-based hypotheses regarding the functional 
roles of RNA cytosine methylation and methyltransferases. Based on such results, the 
generation of knockout mice and morphant fish lacking specific m5C-RMTs will be prioritized. In 
addition the nature of the targets - interesting small and long noncoding and/or coding RNA 
targets - will be examined in functional contexts to determine the impact of methylation on 




Determining the roles of m5C-RMTs in pathophysiology 
Out of the 10 known human m5C-RMTs, knockout mice are available for 2 of them 
(Dnmt2 and Nsun2). Dnmt2-/- mice do not show any obvious phenotype in normal condition16 
although the involvement of DNMT2 homologues in stress response in fruit fly17 and fission 
yeast18 suggests similar function for the enzyme in human and mouse. Additionally Dnmt2 has 
recently been shown to function in immune response against RNA viruses in fruit fly.19 Nsun2-/- 
mice are viable, but both genders show cyclic alopecia in older animals due to interrupted 
epidermal differentiation programs and males are sterile through an unknown mechanism12. In 
addition, mice with mutations in Nsun7 display male sterility linked to sperm motility defects, 
possibly due to defects in mitochondrial structure and/or function20. Due to the remarkable 
phenotypes linked to Nsun2 and Nsun7, we will pursue targeted experiments to identify the 
functional contribution of methylation to the specific target RNAs identified in the first phase of 
this project, in the etiology of such defects. In addition, based on the results obtained in the first 
phase, generation of knockout mice lacking any other members of the NSUN family 
methyltransferases will be prioritized. Prioritization will also involve additional 
considerations/opportunities. For example, NSUN6 has not been characterized in any organism, 
but uniquely (in the NSUN proteins) bears an additional domain: a special pseudouridine 
synthase and archaeosine transglycosylase (PUA) domain21.  This domain has not been studied in 
NSUN6, and we consider this an opportunity to test its possible involvement in targeting or 
regulation of NSUN6. Interestingly the normalized microarray data (according to RefExA; 
Reference database for gene Expression Analysis (Laboratory for Systems Biology and Medicine 
at RCAST, The University of Tokyo)) report expression restricted to the testes in human. 
Another method for prioritizing the generation of knockout mice models is the 
application of morpholino technology (stable, injectible, antisense oligonucleotides that block 
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RNA translation or splicing) in zebrafish to block the expression of functional m5C-RMT 
homologues in zebrafish. We consider this the fastest and easiest screening tool to explore 
which enzymes are likely important for development of embryos. This preliminary information 
will then be used for rational selection of enzymes for generation of knockout mice or zebrafish 
lines for long-term and more thorough analysis. The knockout or morphant animals will be 
evaluated for several characteristics (viability, morphology, fertility, developmental defects, 
behavior etc.).  Recently, zebrafish researchers at the Huntsman Cancer Institute have been 
developing bioinformatic methods to analyze RNA-seq datasets from early zebrafish embryos, 
methods which can detect the loss of RNAs linked to particular developmental pathways, 
signaling pathways and tissues.  The intended use of this system is for drug screens, but was 
developed using known morpholinos that impaired known pathways and tissues. One can easily 
adapt this system to identify pathways or tissues affected by the loss of a particular m5C-RMT.  
 
Exploring functional models for RNA cytosine methylation  
Considerable effort has been expended by others in understanding the target sites and 
roles of cytosine methylation in tRNAs and rRNAs2. Indeed, roles for RNA cytosine methylation 
have been established, including affecting tRNA folding and stability in normal and stress 
conditions2, 22.  Here, Aza-IP1 promises to greatly expand the known repertoire, and based on 
our results with NSUN2, we expect from several to hundreds of targets per enzyme, and we will 
almost certainly encounter a wide variety of RNA types.  As targets cannot be predicted and 
could span the full spectrum of RNAs, the key issue is prioritization.  RNAs will be prioritized 
based on biological impact of the loss of methylation (assessed above), ‘interest’ in the 
particular target RNA (admittedly subjective, but will focus on impact (see below)), the 
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likelihood that the methylation(s) affects a critical function (is it located at/near a catalytic or 
regulatory site?), and pragmatic issues such as the ease of testing the former issues. We are 
most interested in the possibility that methylation will regulate the catalytic activity of an RNA, 
its interactions with interesting regulatory protein partners, or movement to or activity within a 
particular compartment and the likelihood that our efforts will inform and impact an important 
problem in basic science or the pathophysiology observed in human disease.  
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Table A.1: Methylation report for candidate m5C sites in protein coding genes (mRNAs)  
from wt and dnmt2-/- datasets 
















Gene Nus1 Chr10:52137825 nogo-B receptor precursor 91 64.84 110 60.55 
3'-
UTR 
1110067D22Rik Chr11:20725147 galectin-related protein A 14 7.14 13 23.08 
3'-
UTR 
2310022B05Rik Chr8:127160378 hypothetical protein LOC69551 56 8.93 33 24.24 
Gene 2310047M10Rik Chr11:68873931 hypothetical protein LOC71923 15 60 21 47.62 
Gene 2510039O18Rik Chr4:147318738 hypothetical protein LOC77034 
precursor 
532 14.5 684 22.03 
Gene 2900010M23Rik Chr17:27259735 hypothetical protein LOC67267 266 24.81 232 27.71 
3'-
UTR 
5930416I19Rik Chr6:128308096 Uncharacterized protein 
C12orf32 homolog 
10 40 3 0 
3'-
UTR 
Abhd8 Chr8:73981072 abhydrolase domain-containing 
protein 8 
34 2.94 22 40.91 
Gene Abr Chr11:76277078 active breakpoint cluster 
region-related protein 
16 50 23 52.17 
5'-
UTR 
Acbd6 Chr1:157405570 acyl-CoA-binding domain-
containing protein 6 
11 27.27 5 0 
Gene Actg2 Chr6:83477368 actin, gamma-enteric smooth 
muscle 
63 20.63 342 13.16 
3'-
UTR 
Adipor2 Chr6:119304362 adiponectin receptor protein 2 14 7.14 15 26.67 
Gene Aes Chr10:81028349 amino-terminal enhancer of 
split 
110 40.91 80 36.25 
Gene Aftph Chr11:20627446 hypothetical protein 13 23.08 10 10 
Gene Ak5 Chr3:152278926 adenylate kinase isoenzyme 5 10 22.22 11 18.18 
3'-
UTR 
Anapc13 Chr9:102536533 anaphase-promoting complex 
subunit 13 
15 6.67 17 25 
3'-
UTR 
Ap1ar Chr3:127510835 adaptor-related protein 
complex 1 associated 
14 28.57 14 21.43 
3'-
UTR 
Ap3s2 Chr7:87024243 AP-3 complex subunit sigma-2 5 20 13 23.08 
Gene App Chr16:85013884 amyloid beta A4 protein 
isoform 1 precursor 
793 22.47 410 25.12 
3'-
UTR 
Arf1 Chr11:59025466 ADP-ribosylation factor 1 196 32.14 263 24.33 
Gene Arf3 Chr15:98571471 ADP-ribosylation factor 3 132 41.22 148 40.54 
Gene Arid1b Chr17:4995476 AT rich interactive domain 1B 
(SWI1-like) 
9 11.11 13 30.77 
3'-
UTR 
Atf5 Chr7:52068324 cyclic AMP-dependent 
transcription factor ATF-5 
14 42.86 6 16.67 
3'-
UTR 
Atf5 Chr7:52068362 cyclic AMP-dependent 
transcription factor ATF-5 
13 23.08 4 50 
3'-
UTR 
Atp2a2 Chr5:122909562 sarcoplasmic/endoplasmic 
reticulum calcium 
22 27.27 13 23.08 
Gene Atp6v0a1 Chr11:100888602 V-type proton ATPase 116 kDa 
subunit a isoform 
30 43.33 20 30 
126 
 


















Atp6v1a Chr16:44086715 V-type proton ATPase catalytic 
subunit A 
21 28.57 16 18.75 
3'-
UTR 
Axl Chr7:26543418 tyrosine-protein kinase 
receptor UFO isoform 1 
346 18.55 501 21.16 
3'-
UTR 
B4galt2 Chr4:117555866 beta-1,4-galactosyltransferase 2 25 48 25 52 
Gene Bag6 Chr17:35279732 large proline-rich protein BAT3 18 66.67 7 42.86 
3'-
UTR 
Banf1 Chr19:5365005 barrier-to-autointegration 
factor 
90 35.56 121 32.23 
Gene BC018507 Chr13:70745097 mKIAA0947 protein 13 23.08 7 0 
5'-
UTR 
Bdnf Chr2:109533855 brain-derived neurotrophic 
factor isoform 1 
38 21.05 28 17.86 
3'-
UTR 
Bicc1 Chr10:70387944 Protein bicaudal C homolog 1 7 42.86 16 31.25 
Gene Cad Chr5:31363290 carbamoyl-phosphate 
synthetase 2, aspartate 
16 18.75 11 27.27 
Gene Ccdc107 Chr4:43508228 coiled-coil domain-containing 
protein 107 
35 71.43 30 86.67 
3'-
UTR 
Ccni Chr5:93611961 cyclin-I 39 23.08 40 17.5 
Gene Cd109 Chr9:78484404 CD109 antigen precursor 63 36.51 20 25 
Gene Cd109 Chr9:78515082 CD109 antigen precursor 67 59.7 21 66.67 
Gene Cd109 Chr9:78527910 CD109 antigen precursor 67 7.46 24 21.74 
3'-
UTR 
Cdca4 Chr12:114058788 cell division cycle-associated 
protein 4 
16 25 18 38.89 
Gene Cenpb Chr2:131004566 major centromere autoantigen 
B 
30 33.33 28 71.43 
Gene Cgrrf1 Chr14:47465617 cell growth regulator with RING 
finger domain 
25 40 13 46.15 
Gene Chchd3 Chr6:33010075 coiled-coil-helix-coiled-coil-helix 59 35.59 41 29.27 
Gene Chd3 Chr11:69161295 Chd3 protein 82 6.1 30 20 
Gene Chd3 Chr11:69173788 chromodomain helicase DNA 
binding protein 3 
105 30.48 65 30.77 
Gene Chmp1a Chr8:125731402 charged multivesicular body 
protein 1a 
240 28.75 253 38.89 
Gene Chpf Chr1:75472421 chondroitin sulfate synthase 2 
isoform b 
26 61.54 27 25.93 
3'-
UTR 
Chpf Chr1:75471517 chondroitin sulfate synthase 2 
isoform b 
14 28.57 10 11.11 
Gene Chst2 Chr9:95306155 carbohydrate sulfotransferase 2 2 50 12 33.33 
Gene Col1a1 Chr11:94803372 collagen alpha-1(I) chain 
precursor 
729 38.65 476 30.3 
Gene Col1a1 Chr11:94805126 collagen alpha-1(I) chain 
precursor 
565 24.16 485 21.86 
Gene Col4a1 Chr8:11233892 collagen alpha-1(IV) chain 
precursor 
63 28.57 77 27.27 
Gene Col4a5 ChrX:138065880 collagen, type IV, alpha 5 37 78.38 48 66.67 
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Gene Col5a2 Chr1:45438971 collagen alpha-2(V) chain 
precursor 
126 19.84 163 26.99 
Gene Col6a3 Chr1:92670141 collagen, type VI, alpha 3 1 100 21 66.67 
Gene Col6a3 Chr1:92678637 collagen, type VI, alpha 3 0 0 20 25 
Gene Copg Chr6:87852347 coatomer subunit gamma 
isoform 1 
140 30.71 148 25 
Gene Copg Chr6:87852348 coatomer subunit gamma 
isoform 1 
141 22.7 149 17.45 
Gene Copg Chr6:87852358 coatomer subunit gamma 
isoform 1 
139 23.02 137 18.98 
Gene Copg Chr6:87852359 coatomer subunit gamma 
isoform 1 
139 21.58 136 18.38 
3'-
UTR 
Cotl1 Chr8:122333604 coactosin-like protein 17 52.94 72 54.17 
3'-
UTR 
Cpd Chr11:76593325 carboxypeptidase D precursor 8 0 19 26.32 
Gene Crtap Chr9:114299351 cartilage-associated protein 
precursor 
33 42.42 24 45.83 
Gene Ctnnd1 Chr2:84460581 catenin delta-1 isoform 2 75 10.67 77 28.57 
Gene Cttn Chr7:151622878 src substrate cortactin 50 12 49 20.41 
Gene Cul5 Chr9:53475259 cullin-5 isoform 1 23 18.18 20 30 
Gene Cul7 Chr17:46788742 uncharacterized protein 17 11.76 10 20 
Gene Cul7 Chr17:46798682 uncharacterized protein 22 22.73 15 13.33 
3'-
UTR 
Dcakd Chr11:102855858 dephospho-CoA kinase domain-
containing protein 
10 40 6 16.67 
Gene Ddx54 Chr5:121068727 ATP-dependent RNA helicase 
DDX54 
20 35 20 30 
Gene Dlc1 Chr8:37642668 rho GTPase-activating protein 7 
isoform 2 
21 23.81 13 0 
Gene Dnajc10 Chr2:80173941 dnaJ homolog subfamily C 
member 10 
68 14.71 78 23.08 
Gene Dnajc3 Chr14:119377347 dnaJ homolog subfamily C 
member 3 precursor 
20 30 10 20 
Gene Donson Chr16:91688778 protein downstream neighbor 
of Son 
23 21.74 28 14.29 
3'-
UTR 
Ebp ChrX:7762683 3-beta-hydroxysteroid-Delta(8) 10 40 11 45.45 
Gene Ecm1 Chr3:95538207 extracellular matrix protein 1 
precursor 
17 41.18 18 38.89 
3'-
UTR 
Eif4ebp1 Chr8:28385714 eukaryotic translation initiation 
factor 
42 30.95 35 25.71 
Gene Emb Chr13:118056195 embigin precursor 7 0 16 25 
Gene Emd ChrX:71502521 emerin 141 25.53 274 26.28 
Gene Ergic3 Chr2:155836875 endoplasmic reticulum-Golgi 
intermediate 
189 14.81 145 20.69 
Gene Exosc10 Chr4:147954583 exosome component 10 22 22.73 17 17.65 
3'-
UTR 
Extl3 Chr14:65672410 exostosin-like 3 12 25 15 26.67 
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Gene Fam108a Chr10:80048407 abhydrolase domain-containing 
protein FAM108A 
205 14.63 203 22.17 
3'-
UTR 
Fam195b Chr11:120404476 hypothetical protein LOC192173 13 23.08 23 17.39 
Gene Fam38a Chr8:125010407 protein PIEZO1 53 18.87 40 20 
Gene Fam38a Chr8:125026116 protein PIEZO1 10 33.33 7 71.43 
Gene Farsa Chr8:87384870 phenylalanyl-tRNA synthetase 
alpha chain 
12 33.33 9 22.22 
Gene Fasn Chr11:120680359 fatty acid synthase 32 18.75 21 38.1 
Gene Fasn Chr11:120680421 fatty acid synthase 10 40 6 16.67 
Gene Fbln2 Chr6:91218539 fibulin-2 isoform a 1427 79.17 1450 82.88 
Gene Fbn1 Chr2:125128841 fibrillin-1 555 26.49 676 15.56 
Gene Fbn1 Chr2:125147358 fibrillin-1 67 73.13 83 69.88 
Gene Fkbp4 Chr6:128380828 peptidyl-prolyl cis-trans 
isomerase FKBP4 
102 11.76 77 21.05 
Gene Flna ChrX:71482483 filamin-A 93 19.57 99 27.27 
Gene Flnb Chr14:8717116 filamin-B 128 18.75 167 23.35 
Gene Frmd4a Chr2:4524623 FERM domain-containing 
protein 4A isoform 1 
16 0 14 28.57 
Gene Fscn1 Chr5:143722899 fascin 71 57.75 76 53.95 
Gene Ftl1 Chr7:52713562 ferritin light chain 1 290 23.96 165 18.79 
3'-
UTR 
Fzd1 Chr5:4755213 frizzled-1 precursor 21 33.33 27 48.15 
Gene Galnt10 Chr11:57579160 polypeptide N-
acetylgalactosaminyltransferase 
13 30.77 7 42.86 
Gene Galnt2 Chr8:126819327 polypeptide N-
acetylgalactosaminyltransferase 
2 
247 20.65 286 25.52 
Gene Galnt2 Chr8:126860484 polypeptide N-
acetylgalactosaminyltransferase 
2 
95 22.11 112 13.39 
Gene Galnt2 Chr8:126860488 polypeptide N-
acetylgalactosaminyltransferase 
2 
99 27.27 119 21.85 
3'-
UTR 
Galnt2 Chr8:126868752 polypeptide N-
acetylgalactosaminyltransferase 
2 
14 7.14 22 31.82 
Gene Gas2l1 Chr11:4962229 GAS2-like protein 1 isoform 
alpha 
41 22.5 40 20 
Gene Ghr Chr15:3269874 growth hormone receptor 
isoform 1 precursor 
19 0 20 25 
Gene Glis3 Chr19:28432378 zinc finger protein GLIS3 14 21.43 26 50 
3'-
UTR 
Glo1 Chr17:30729915 lactoylglutathione lyase 19 21.05 31 9.68 
Gene Gnb2l1 Chr11:48614047 guanine nucleotide-binding 
protein subunit 
1299 29.71 1080 20.09 
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Gorab Chr1:165315670 RAB6-interacting golgin 4 50 19 52.63 
3'-
UTR 
Gosr2 Chr11:103539940 Golgi SNAP receptor complex 
member 2 
36 27.78 35 25.71 
3'-
UTR 
Got2 Chr8:98388904 aspartate aminotransferase, 
mitochondrial 
17 47.06 22 40.91 
Gene Gpd2 Chr2:57142306 glycerol-3-phosphate 
dehydrogenase 
34 57.58 25 76 
3'-
UTR 
Grem2 Chr1:176765226 gremlin-2 precursor 2 0 36 38.89 
Gene Gvin1 Chr7:113047862 interferon-induced very large 
GTPase 1 
52 28.85 8 12.5 
Gene Gvin1 Chr7:113304279 interferon-induced very large 
GTPase 1 
50 20 7 14.29 
Gene Hdgf Chr3:87718567 hepatoma-derived growth 
factor 
234 25.75 212 27.96 
Gene Herc4 Chr10:62780097 probable E3 ubiquitin-protein 
ligase HERC4 
23 8.7 24 20.83 
Gene Hist1h2ai Chr13:21808490 histone H2A type 1 94 20.21 181 28.18 
Gene Hist1h2ai Chr13:21808494 histone H2A type 1 88 28.41 178 29.94 
Gene Hist1h2ai Chr13:21808502 histone H2A type 1 72 29.17 153 30.72 
Gene Hist1h2ai Chr13:21808503 histone H2A type 1 70 35.71 149 33.56 
Gene Hist1h2ai Chr13:21808504 histone H2A type 1 70 31.43 141 36.17 
Gene Hist1h2ai Chr13:21808506 histone H2A type 1 72 27.78 142 30.28 
Gene Hist2h2ab Chr3:96024038 histone H2A type 2-B 54 15.09 71 28.17 
Gene Hist2h2ab Chr3:96024042 histone H2A type 2-B 52 21.15 68 25 
Gene Hist2h2ab Chr3:96024050 histone H2A type 2-B 36 22.22 60 28.33 
Gene Hist2h2ab Chr3:96024051 histone H2A type 2-B 35 25.71 54 27.78 
Gene Hist2h2ab Chr3:96024052 histone H2A type 2-B 33 21.21 53 26.42 
Gene Hist2h2ab Chr3:96024054 histone H2A type 2-B 32 9.38 53 28.3 
Gene Homer3 Chr8:72813338 homer protein homolog 3 
isoform 2 
112 20.54 72 23.61 
Gene Hspg2 Chr4:137096135 basement membrane-specific 
heparan sulfate 
65 15.38 36 22.22 
Gene Htra1 Chr7:138079898 serine protease HTRA1 
precursor 
43 34.88 59 35.59 
Gene Igf1r Chr7:75148812 insulin-like growth factor 1 
receptor 
166 22.89 86 22.35 
Gene Igf2r Chr17:12891204 cation-independent mannose-6-
phosphate receptor 
432 36.81 444 27.03 
Gene Igf2r Chr17:12891205 cation-independent mannose-6-
phosphate receptor 
429 48.6 445 39.19 
3'-
UTR 
Igf2r Chr17:12876061 cation-independent mannose-6-
phosphate receptor 
24 33.33 33 30.3 
Gene Igfbp6 Chr15:101979684 insulin-like growth factor-
binding protein 6 
1 0 28 46.43 
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Il13ra1 ChrX:33710599 interleukin-13 receptor subunit 
alpha-1 
7 28.57 15 20 
Gene Il6st Chr13:113270418 Putative uncharacterized 
protein 
26 53.85 36 75 
Gene Ints1 Chr5:140235242 integrator complex subunit 1 30 16.67 15 33.33 
3'-
UTR 
Ints3 Chr3:90195457 integrator complex subunit 3 15 26.67 9 33.33 
Gene Jund Chr8:73223528 transcription factor jun-D 11 45.45 6 33.33 
Gene Katnb1 Chr8:97619573 katanin p80 WD40-containing 
subunit B1 
42 66.67 43 65.12 
Gene Kdelc2 Chr9:53198635 KDEL (Lys-Asp-Glu-Leu) 
containing 2 protein 
25 12 13 30.77 
Gene Klhl26 Chr8:72979480 kelch-like protein 26 isoform 2 6 16.67 11 36.36 
3'-
UTR 
Lamp2 ChrX:35774191 lysosome-associated membrane 
glycoprotein 2 
101 16.16 82 36.59 
3'-
UTR 
Litaf Chr16:10960142 lipopolysaccharide-induced 
tumor necrosis 
9 55.56 12 25 
Gene Loxl3 Chr6:82987541 lysyl oxidase homolog 3 
precursor 
78 23.08 110 44.55 
Gene Loxl3 Chr6:82999219 lysyl oxidase homolog 3 
precursor 
50 24 95 39.36 
Gene Lrp1 Chr10:126997169 prolow-density lipoprotein 
receptor-related 
23 60.87 22 63.64 
Gene Lrpprc Chr17:85176387 leucine-rich PPR motif-
containing protein 
20 0 16 25 
3'-
UTR 
Lrrc15 Chr16:30269503 leucine-rich repeat-containing 
protein 15 
4 25 13 46.15 
3'-
UTR 
Lrrc15 Chr16:30272784 leucine-rich repeat-containing 
protein 15 
3 66.67 10 50 
3'-
UTR 
Lrrc15 Chr16:30272785 leucine-rich repeat-containing 
protein 15 
3 33.33 10 50 
Gene Lrrc45 Chr11:120582033 leucine-rich repeat-containing 
protein 45 
17 52.94 5 60 
Gene Lta4h Chr10:92943517 leukotriene A-4 hydrolase 21 38.1 16 31.25 
Gene Mapk1ip1l Chr14:47930401 MAPK-interacting and spindle-
stabilizing 
21 23.81 12 16.67 
Gene Marcks Chr10:36856328 myristoylated alanine-rich C-
kinase substrate 
20 30 10 0 
Gene Mardh5 Chr19:37285270 E3 ubiquitin-protein ligase 
MARCH5 isoform 3 
10 30 13 0 
5'-
UTR 
Masp1 Chr16:23520645 mannan-binding lectin serine 
protease 1 
142 16.2 63 22.22 
3'-
UTR 
Metap1 Chr3:138122647 methionine aminopeptidase 1 46 10.87 44 20.45 
3'-
UTR 
Mlec Chr5:115594247 malectin precursor 253 25.3 178 23.6 
3'-
UTR 
Mlec Chr5:115595374 malectin precursor 34 23.53 17 23.53 
3'-
UTR 
Mpdu1 Chr11:69470585 mannose-P-dolichol utilization 
defect 1 protein 
21 4.76 11 27.27 
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Gene Msl1 Chr11:98657418 male-specific lethal 1 homolog 10 40 11 36.36 
Gene Mtap1b Chr13:100205214 microtubule-associated protein 
1B 
35 20 20 30 
3'-
UTR 
Mtf1 Chr4:124526963 metal regulatory transcription 
factor 1 
34 20.59 35 17.14 
Gene Mvp Chr7:134130532 major vault protein 23 30.43 6 33.33 
3'-
UTR 
Myef2 Chr2:124913772 sodium/potassium/calcium 
exchanger 5 precursor 
11 9.09 13 30.77 
3'-
UTR 
Nap1l4 Chr7:150700445 nucleosome assembly protein 
1-like 4 
40 25 48 20.83 
Gene Ncln Chr10:80952623 nicalin precursor 35 8.57 15 20 
3'-
UTR 
Necap2 Chr4:140622641 adaptin ear-binding coat-
associated protein 2 
41 17.07 27 33.33 
3'-
UTR 
Nedd4 Chr9:72596630 E3 ubiquitin-protein ligase 
NEDD4 
114 15.79 92 28.26 
3'-
UTR 
Nek9 Chr12:86641347 serine/threonine-protein kinase 
Nek9 
30 50 14 57.14 
3'-
UTR 
Nfe2l1 Chr11:96678920 nuclear factor erythroid 2-
related factor 1 
12 25 7 0 
Gene Nfix Chr8:87296194 nuclear factor 1 X-type isoform 
3 
9 66.67 17 70.59 
Gene Nid2 Chr14:20571674 nidogen-2 precursor 28 89.29 10 90 
3'-
UTR 
Nme4 Chr17:26228949 nucleoside diphosphate kinase, 
mitochondrial 
21 23.81 14 7.14 
Gene Nmt2 Chr2:3201573 N-myristoyltransferase 2 31 12.9 28 21.43 
Gene Nono ChrX:98637056 non-POU domain-containing 
octamer-binding 
59 15.25 52 25 
Gene Nuak1 Chr10:83903014 NUAK family SNF1-like kinase 1 19 31.58 7 42.86 
Gene Pacs2 Chr12:114288095 phosphofurin acidic cluster 
sorting protein 2 
18 22.22 18 33.33 
Gene Pcdha4-g Chr18:37645376 protocadherin alpha 4-gamma 14 57.14 16 93.75 
Gene Pcdha4-g Chr18:37966649 protocadherin alpha 4-gamma 19 26.32 10 20 
3'-
UTR 
Pfkl Chr10:77450778 6-phosphofructokinase, liver 
type 
12 25 11 18.18 
Gene Pitpna Chr11:75433756 phosphatidylinositol transfer 
protein alpha 
97 19.59 71 32.39 
Gene Pitrm1 Chr13:6554876 presequence protease, 
mitochondrial precursor 
150 29.33 137 27.01 
3'-
UTR 
Plbd2 Chr5:120934131 putative phospholipase B-like 2 11 45.45 5 20 
Gene Plec Chr15:76006893 plectin isoform 1a 18 22.22 16 6.25 
Gene Plec Chr15:76008546 plectin isoform 1a 4 25 11 30 
Gene Plec Chr15:76008556 plectin isoform 1a 4 0 12 50 
Gene Plec Chr15:76008566 plectin isoform 1a 3 33.33 11 72.73 
Gene Plec Chr15:76008577 plectin isoform 1a 5 40 10 30 
Gene Plec Chr15:76011740 plectin isoform 1a 16 25 8 0 
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Gene Plec Chr15:76012154 plectin isoform 1a 9 77.78 11 36.36 
Gene Plec Chr15:76012164 plectin isoform 1a 8 75 11 54.55 
Gene Plec Chr15:76012188 plectin isoform 1a 11 0 13 23.08 
Gene Plec Chr15:76018177 plectin isoform 1a 22 9.09 12 25 
Gene Plekhg2 Chr7:29155352 pleckstrin homology domain-
containing family G 
21 38.1 14 28.57 
Gene Plod1 Chr4:147305292 procollagen-lysine,2-
oxoglutarate 5-dioxygenase 
32 46.88 55 56.36 
Gene Plxnb2 Chr15:88991468 Similar to plexin B1 22 45.45 14 64.29 
3'-
UTR 
Pmepa1 Chr2:173050276 transmembrane prostate 
androgen-induced protein 
23 13.04 21 23.81 
3'-
UTR 
Poldip3 Chr15:82957356 polymerase delta-interacting 
protein 3 
155 42.58 160 54.09 
Gene Ppp1cc Chr5:122619025 serine/threonine-protein 
phosphatase PP1-gamma 
20 10 12 25 
3'-
UTR 
Psma4 Chr9:54805706 proteasome subunit alpha type-
4 
34 67.65 70 71.43 
3'-
UTR 
Psmb7 Chr2:38443660 proteasome subunit beta type-7 
precursor 
64 40.62 58 46.55 
Gene Psmd7 Chr8:110105103 26S proteasome non-ATPase 
regulatory subunit 7 
30 20 23 30.43 
Gene Psme4 Chr11:30712067 proteasome activator complex 
subunit 4 
46 28.26 36 33.33 
Gene Ptdss1 Chr13:67073461 phosphatidylserine synthase 1 32 53.12 48 63.83 
3'-
UTR 
Ptplad1 Chr9:64835631 3-hydroxyacyl-CoA dehydratase 
3 
19 15.79 18 27.78 
Gene Ptprn Chr1:75248328 receptor-type tyrosine-protein 
phosphatase-like 
48 54.17 63 63.49 
Gene Ptprn Chr1:75254850 receptor-type tyrosine-protein 
phosphatase-like 
30 23.33 33 27.27 
3'-
UTR 
Ptprn Chr1:75243938 receptor-type tyrosine-protein 
phosphatase-like 
11 54.55 6 66.67 
Gene Pttg1ip Chr10:77055720 pituitary tumor-transforming 
gene 1 
120 14.17 88 32.95 
Gene Pttg1ip Chr10:77055752 pituitary tumor-transforming 
gene 1 
36 17.14 38 39.47 
3'-
UTR 
Purb Chr11:6372307 purine rich element binding 
protein B (Purb) 
6 0 14 21.43 
3'-
UTR 
Rai14 Chr15:10499343 ankycorbin 8 12.5 33 27.27 
3'-
UTR 
Rb1 Chr14:73597011 retinoblastoma-associated 
protein 
30 13.33 24 25 
Gene Rpl34 Chr3:130432050 60S ribosomal protein L34 
isoform 1 
274 28.47 276 13.82 
Gene Rps6ka4 Chr19:6904554 ribosomal protein S6 kinase 
alpha-4 
86 20.24 45 8.89 
3'-
UTR 
Rspo3 Chr10:29173572 R-spondin-3 precursor 17 25 5 0 
Gene Sae1 Chr7:16973041 SUMO-activating enzyme subunit 1 75 33.78 47 27.66 
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Gene Sae1 Chr7:16973058 SUMO-activating enzyme 
subunit 1 
22 57.14 16 37.5 
3'-
UTR 
Sec61a1 Chr6:88453783 protein transport protein Sec61 
subunit alpha 
65 56.92 40 80 
3'-
UTR 
Sepn1 Chr4:134095447 selenoprotein N, 1 27 22.22 5 0 
Gene Setbp1 Chr18:79283442 SET-binding protein 13 53.85 3 66.67 
Gene Setd3 Chr12:109403360 SET domain-containing protein 3 22 9.09 23 26.09 
Gene Sgce Chr6:4641572 epsilon-sarcoglycan isoform 1 27 23.08 17 35.29 
3'-
UTR 
Sgpl1 Chr10:60561833 sphingosine-1-phosphate lyase 1 31 22.58 43 20.93 
3'-
UTR 
Sgta Chr10:80507347 small glutamine-rich 
tetratricopeptide 
34 50 18 66.67 
3'-
UTR 
Sirt7 Chr11:120480109 NAD-dependent deacetylase 
sirtuin-7 
15 26.67 8 25 
3'-
UTR 
Slc23a2 Chr2:131881811 sodium-dependent vitamin C 
transporter SVCT2 
12 16.67 10 20 
Gene Slc25a4 Chr8:47294488 ADP/ATP translocase 1 239 39.75 268 31.2 
3'-
UTR 
Slc35a3 Chr3:116373862 UDP-N-acetylglucosamine 
transporter 
10 40 17 29.41 
Gene Slc38a10 Chr11:119966810 sodium-coupled neutral amino acid 83 26.51 62 20.97 
Gene Slc39a1 Chr3:90055623 zinc transporter ZIP1 147 58.5 138 65.22 
Gene Smpd1 Chr7:112704250 uncharacterized protein 141 22.7 107 26.17 
Gene Snora21 Chr11:97643136 60S ribosomal protein L23 1100 24.82 1156 13.49 
3'-
UTR 
Sorcs2 Chr5:36360777 VPS10 domain-containing 
receptor 
12 83.33 10 100 
Gene Spag9 Chr11:93975571 C-Jun-amino-terminal kinase-
interacting protein 
117 20.51 70 32.86 
Gene Srp68 Chr11:116122186 signal recognition particle 68 
kDa protein 
19 15.79 16 25 
3'-
UTR 
Stom Chr2:35171342 erythrocyte band 7 integral 
membrane protein 






20 25 20 10 
3'-
UTR 
Surf4 Chr2:26776217 surfeit locus protein 4 530 33.96 648 43.06 
Gene Syne2 Chr12:77068376 nesprin-2 11 27.27 10 20 
Gene Taf10 Chr7:112892449 transcription initiation factor 
TFIID subunit 
10 40 7 28.57 
3'-
UTR 
Tagln Chr9:45737989 transgelin 19 31.58 41 0 
3'-
UTR 
Tardbp Chr4:147999265 TAR DNA-binding protein 43 
isoform 4 
111 16.67 87 29.89 
5'-
UTR 
Tcf12 Chr9:71959546 transcription factor 12 17 52.94 10 40 
3'-
UTR 
Tcn2 Chr11:3817359 transcobalamin-2 precursor 25 60 29 62.07 
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Gene Tgfb3 Chr12:87410750 transforming growth factor 
beta-3 preproprotein 
33 36.36 50 26 
Gene Tgm2 Chr2:157943597 protein-glutamine gamma-
glutamyltransferase 2 
21 9.52 28 25 
Gene Tm9sf1 Chr14:56255332 transmembrane 9 superfamily 
member 1 precursor 
16 12.5 13 23.08 
5'-
UTR 
Tmem126a Chr7:97605648 transmembrane protein 126A 35 37.14 37 29.73 
Gene Tmem132a Chr19:10934155 transmembrane protein 132A 
precursor 
20 10 10 40 
Gene Tmem132a Chr19:10939958 transmembrane protein 132A 
precursor 
15 20 2 0 
3'-
UTR 
Tmem161a Chr8:72706281 transmembrane protein 161A 
precursor 
12 8.33 12 25 
Gene Tmem198b Chr10:128239114 hypothetical protein LOC73827 13 0 25 24 
Gene Tmem2 Chr19:21881978 transmembrane protein 2 12 33.33 11 9.09 
Gene Tpp1 Chr7:112897424 tripeptidyl-peptidase 1 
precursor 
62 67.74 39 69.23 
Gene Tpst2 Chr5:112737342 protein-tyrosine 
sulfotransferase 2 
16 12.5 19 52.63 
Gene Tpst2 Chr5:112738760 protein-tyrosine 
sulfotransferase 2 
13 23.08 10 20 
Gene Trap1 Chr16:4045974 heat shock protein 75 kDa, 
mitochondrial 
15 20 22 13.64 
Gene Trim2 Chr3:83994921 tripartite motif-containing 
protein 2 
11 54.55 8 50 
Gene Trp53i13 Chr11:77321783 tumor protein p53-inducible 
protein 13 
26 34.62 15 53.33 
3'-
UTR 
Tspan9 Chr6:127911773 tetraspanin-9 12 33.33 10 20 
3'-
UTR 
Tspan9 Chr6:127913494 tetraspanin-9 20 0 19 31.58 
3'-
UTR 
Tspan9 Chr6:127913495 tetraspanin-9 20 5 20 25 
Gene Ttc7b Chr12:101738357 tetratricopeptide repeat 
domain 7B 
12 25 8 12.5 
Gene Ttll12 Chr15:83421911 tubulin--tyrosine ligase-like 
protein 12 
25 20 36 16.67 
Gene Txndc12 Chr4:108520832 tubulin--tyrosine ligase-like 
protein 12 
26 26.92 32 25 
3'-
UTR 
Ube2z Chr11:95910580 ubiquitin-conjugating enzyme 
E2 Z 
18 5.56 12 25 
3'-
UTR 
Ubiad1 Chr4:147810211 ubiA prenyltransferase domain-
containing protein 
13 46.15 9 22.22 
Gene Ubqln1 Chr13:58293280 ubiquilin-1 isoform 1 68 8.82 77 22.08 
Gene Uqcrfs1 Chr13:30637014 cytochrome b-c1 complex 
subunit Rieske 
8 12.5 12 25 
Gene Use1 Chr8:73891239 vesicle transport protein USE1 
isoform3 
288 25.09 253 11.07 
Gene Use1 Chr8:73893072 vesicle transport protein USE1 
isoform3 
107 32.71 114 25.66 
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Gene Usp38 Chr8:83537771 ubiquitin carboxyl-terminal 
hydrolase 38 
17 5.88 18 33.33 
3'-
UTR 
Wbp2 Chr11:115940271 WW domain-binding protein 2 26 46.15 4 25 
Gene Wdr18 Chr10:79423028 Putative uncharacterized protein 18 22.22 6 16.67 
3'-
UTR 
Wdr48 Chr9:119834545 WD repeat-containing protein 48 14 28.57 13 23.08 
Gene Wdr61 Chr9:54575404 WD repeat-containing protein 
61 isoform a 
51 13.73 47 21.74 
3'-
UTR 
Wwc2 Chr8:48913727 protein WWC2 33 33.33 17 29.41 
3'-
UTR 
Xpo6 Chr7:133245523 Ran-binding protein 20 11 27.27 6 0 
Gene Xylt2 Chr11:94531703 xylosyltransferase 2 15 6.67 10 20 
Gene Zbtb39 Chr10:127179602 zinc finger and BTB domain-
containing protein 
12 25 8 0 
3'-
UTR 
Zdhhc20 Chr14:58453211 probable palmitoyltransferase 
ZDHHC20 
48 22.92 35 20 
Gene Zfhx3 Chr8:111473335 zinc finger homeobox protein 3 22 22.73 21 19.05 
3'-
UTR 
Zfp275 ChrX:70601270 Zinc finger protein 275 isoform 1 25 44 21 38.1 
Gene Zmat3 Chr3:32259939 zinc finger matrin-type protein 3 69 10.14 65 23.08 
3'-
UTR 
Znrf1 Chr8:114145994 E3 ubiquitin-protein ligase 
ZNRF1 isoform a 
5 40 10 50 
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